Clinical trial NCT03509883
Conditions: Healthy Volunteers
Sponsor: Bristol-Myers Squibb
Start date: 2018-04-26; Completion date: 2018-06-15
Enrollment: 94 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
The purpose of this study is to evaluate the absorption of apixaban (BMS-562247) into the bloodstream of healthy volunteers, when administered as sprinkle capsules compared to tablets. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and will receive a single oral dose of apixaban twice during the course of the study.

Detailed description:

Arms: arm 1: Apixaban (BMS-562247) sprinkle capsules followed by apixaban tablets arm 2: Apixaban (BMS-562247) tablets followed by apixaban sprinkle capsules
Interventions: intervention 1: Drug: Apixaban sprinkle capsules intervention 2: Experimental: Apixaban tablets followed by apixaban sprinkle capsules
Intervention descriptions: intervention 1: Single dose (25 x 0.1 mg capsules), oral administration intervention 2: Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration

Protocol documents:
Prot_000.pdf: 
Page:
1
Protocol Number:
CV185687
IND Number:
66,106
EUDRACT Number:
NA
Date:
21-Mar-2018
Clinical Protocol CV185687
Relative Bioavailability of Apixaban (BMS-562247) 0.1-mg Sprinkle Capsules Compared with 
0.5-mg Tablets in Healthy Participants
Medical Monitor
Vanessa Elharrar, MD
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information (eg, amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
confidence in the same manner as the contents of this document. Any person who receives 
this document without due authorization from BMS is requested to return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
to partners to which BMS has transferred obligations, eg, a Contract Research Organization 
(CRO).
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Date: 21-Mar-2018
2
DOCUMENT HISTORY
Document
Date of Issue
Summary of Change
Original 
Protocol
21-Mar-2018
Not applicable
1.0
Approved
930124947
1.0
v


TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................................................................. 
TABLE OF CONTENTS .............................................................................................. 
1 SYNOPSIS ................................................................................................................. 
2 SCHEDULE OF ACTIVITIES.................................................................................. 
3 INTRODUCTION ..................................................................................................... 
3.1 Study Rationale ................................................................................................. 
3.2 Background ....................................................................................................... 
3.3 Benefit/Risk Assessment .................................................................................. 
4 OBJECTIVES AND ENDPOINTS ........................................................................... 
5 STUDY DESIGN....................................................................................................... 
5.1 Overall Design .................................................................................................. 
5.1.1 Data Monitoring Committee and Other External Committees ................ 
5.2 Number of Participants ..................................................................................... 
5.3 End of Study Definition .................................................................................... 
6 STUDY POPULATION ............................................................................................ 
6.1 Inclusion Criteria .............................................................................................. 
6.2 Exclusion Criteria ............................................................................................. 
6.3 Lifestyle Restrictions ........................................................................................ 
6.3.1 Meals and Dietary Restrictions ............................................................... 
6.3.2 Caffeine, Alcohol and Tobacco ................................................................ 
6.3.3 Activity ..................................................................................................... 
6.4 Screen Failures .................................................................................................. 
6.4.1 Retesting During Screening or Lead-In Period ....................................... 
7 TREATMENT ........................................................................................................... 
7.1 Treatments Administered .................................................................................. 
7.2 Method of Treatment Assignment .................................................................... 
7.3 Blinding............................................................................................................. 
7.4 Dosage Modification ......................................................................................... 
7.5 Preparation/Handling/Storage/Accountability .................................................. 
7.5.1 Retained Samples for Bioavailability / Bioequivalence ........................... 
7.6 Treatment Compliance ...................................................................................... 
 
 
7.8 Treatment After the End of the Study ............................................................... 
8 DISCONTINUATION CRITERIA ........................................................................... 
8.1 Discontinuation from Study Treatment ............................................................ 
8.1.1 Post Study Treatment Study Follow-up.................................................... 
8.2 Discontinuation from the Study ........................................................................ 
8.3 Lost to Follow-Up ............................................................................................. 
9 STUDY ASSESSMENTS AND PROCEDURES ..................................................... 
9.1 Efficacy Assessments ........................................................................................ 
1
2
3
6
7
11
11
12
12
13
13
13
14
14
14
15
15
16
18
18
18
18
19
19
19
22
22
23
23
23
23
23
24
24
24
25
25
26
26
27
Clinical Protocol
BMS-562247
CV185687
Apixaban
Date: 21-Mar-2018
3
1.0
Approved
930124947
1.0
v


9.2 Adverse Events ................................................................................................. 
9.2.1 Time Period and Frequency for Collecting AE and SAE Information .... 
9.2.2 Method of Detecting AEs and SAEs ......................................................... 
9.2.3 Follow-up of AEs and SAEs ..................................................................... 
9.2.4 Regulatory Reporting Requirements for SAEs ......................................... 
9.2.5 Pregnancy ................................................................................................ 
9.2.6 Laboratory Test Result Abnormalities ..................................................... 
9.2.7 Potential Drug-Induced Liver Injury (DILI) ............................................ 
9.2.8 Other Safety Considerations .................................................................... 
9.3 Overdose ........................................................................................................... 
9.4 Safety ................................................................................................................ 
9.4.1 Physical Examinations ............................................................................. 
9.4.1.1 Rash Photography ........................................................................... 
9.4.2 Vital Signs ................................................................................................ 
9.4.3 Electrocardiograms ................................................................................. 
9.4.4 Clinical Safety Laboratory Assessments .................................................. 
9.4.5 Suicidal Risk Monitoring ......................................................................... 
9.4.6 Imaging Safety Assessment ...................................................................... 
9.4.7 Physical Measurements ........................................................................... 
9.4.8 Medical History ....................................................................................... 
9.4.9 Adverse Event Monitoring ....................................................................... 
9.5 Pharmacokinetics .............................................................................................. 
9.6 Pharmacodynamics ........................................................................................... 
9.7 Pharmacogenomics ........................................................................................... 
 
 
 
9.9 Health Economics OR Medical Resource Utilization and Health Economics . 
10 STATISTICAL CONSIDERATIONS .................................................................... 
10.1 Sample Size Determination ............................................................................. 
10.2 Populations for Analyses ................................................................................ 
10.3 Statistical Analyses ......................................................................................... 
10.3.1 Demographics and Baseline Characteristics......................................... 
10.3.2 Efficacy Analyses ................................................................................... 
10.3.3 Safety Analyses....................................................................................... 
10.3.4 Pharmacokinetic Analyses ..................................................................... 
10.3.5 Interim Analyses ..................................................................................... 
. 
12 APPENDICES ......................................................................................................... 
. 
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS ................................. 
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW-UP, AND REPORTING ....................................................................... 
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION ..................................................................... 
27
27
28
28
28
28
29
29
30
30
30
30
30
30
30
30
31
31
32
32
32
32
33
33
35
35
35
36
36
36
36
37
37
38
40
43
51
55
Clinical Protocol
BMS-562247
CV185687
Apixaban
Date: 21-Mar-2018
4
1.0
Approved
930124947
1.0
v


APPENDIX 5 DIAGNOSTIC CRITERIA FOR DRUG AND ALCOHOL ABUSE .. 
 
59
Clinical Protocol
BMS-562247
CV185687
Apixaban
Date: 21-Mar-2018
5
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
1
SYNOPSIS
Not applicable.
Date: 21-Mar-2018
6
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
2
SCHEDULE OF ACTIVITIES
Study assessments and procedures are presented in Table 2-1 and Table 2-2.
Table 2-1:
Screening Procedural Outline (CV185687)
Procedure
Screening Visit
(Day -28 to Day -2)
Admission Visit
(Day -1)
Notes
Eligibility Assessments
Informed Consent
X
A participant is considered enrolled only when a protocol-specific 
informed consent is signed.
Inclusion/Exclusion Criteria
X
X
Medical History
X
X
A complete medical history will be obtained during screening. Interim 
medical history on Day -1. Include any toxicities or allergy related to 
previous treatments.
Report to Study Site
X
Safety Assessments
Physical Examination
X
X
The physical examination performed on Day -1 should be done within 
24 hours of dosing on Day 1.
Starting on Day –1, standard baseline medical dermatology 
photographs of areas affected by rash will be taken. If there are any 
changes with the affected areas or new areas of rash are detected, 
additional photographs will be obtained.
Physical Measurements
X
X
Height and weight at screening; weight only on Day -1. Body mass 
index will be calculated at screening and on Day -1.
Vital Signs
X
X
Includes body temperature, respiratory rate, and sitting blood pressure 
and heart rate. Blood pressure and heart rate should be measured after 
the participant has been sitting for at least 5 minutes.
12-Lead ECGs
X
X
12-lead ECGs should be recorded after the participant has been supine 
for at least 5 minutes. 
Clinical Laboratory Tests
X
X
Includes blood and urine samples. Full clinical laboratory tests will be 
done including coagulation parameters (aPTT, INR, and PT) will be 
measured. Participants are required to fast for at least 8 hours prior to 
Date: 21-Mar-2018
7
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Table 2-1:
Screening Procedural Outline (CV185687)
Procedure
Screening Visit
(Day -28 to Day -2)
Admission Visit
(Day -1)
Notes
the collection of specimens for clinical laboratory tests. Results of 
screening clinical laboratory tests must be available prior to admission 
to the clinic on Day -1. Results of clinical laboratory tests performed 
on Day -1 must be available prior to dosing on Day 1. See 
Section 9.4.4.
Serology
X
Results must be reviewed prior to admission to the clinic on Day -1. 
See Section 9.4.4.
Urine Drug Test
X
X
Includes alcohol and cotinine. Results of screening urine drug tests 
must be available prior to admission to the clinic on Day -1. Results of 
urine drug tests performed on Day -1 must be within 24 hours and 
reviewed prior to dosing on Day 1. See Section 9.4.4.
Pregnancy Test (serum)
X
X
All women. Results of pregnancy tests must be available prior to
admission to the clinic on Day -1. The pregnancy test on Day -1 must 
be within approximately 24 hours, and results must be available prior 
to dosing on Day 1. Serum pregnancy tests must be reported in a 
quantitative result.
Follicle Stimulating Hormone
X
Postmenopausal women only. Refer to Appendix 4.
Adverse Event Reporting
Monitor for SAEs
X
X
All SAEs must be collected from the date of participant’s written 
consent until 30 days post discontinuation of dosing or participant’s 
participation in the study if the last scheduled visit occurs at a later 
time.
aPTT = activated partial thromboplastin time; ECG = electrocardiogram; INR = international normalized ratio; PT = prothrombin time; SAE = serious adverse 
event
Date: 21-Mar-2018
8
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Table 2-2:
On Treatment Procedural Outline (CV185687)
Procedure
D1
D2 
D3
D4
D5
D6
D7
D8
(Study Discharge)a
Notes
Safety Assessments
Physical Examination
X
X
Day 4 physical examination targeted for skin 
will be performed within 24 hours of dosing
on Day 5. Starting on Day –1, standard 
baseline medical dermatology photographs of 
areas affected by rash will be taken. If there 
are any changes with the affected areas or 
new areas of rash are detected, additional 
photographs will be obtained.
Physical Measurements 
X
Weight only.
Vital Signs
X
X
X
Vital signs will be obtained prior to dosing on 
Days 1 and 5. See note in screening 
procedures.
12-Lead ECGs
X
X
12-lead ECGs on Day 5 will be obtained prior 
to dosing. See note in screening procedures. 
Clinical Laboratory Tests
X
X
Includes blood and urine samples. Full 
clinical laboratory tests will be done including 
coagulation parameters (aPTT, INR, and PT)
will be measured on Days 4 and 7. Results of 
clinical laboratory tests performed on Day 4 
must be available prior to dosing on Day 5.
See note in screening procedures and 
Section 9.4.4.
Pregnancy Test (serum)
X
X
Serum pregnancy testing must be done within 
approximately 24 hours of Day 5. Results 
must be reviewed prior to dosing on Day 5.
Serum pregnancy tests must be reported in a 
quantitative result.
Date: 21-Mar-2018
9
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Table 2-2:
On Treatment Procedural Outline (CV185687)
Procedure
D1
D2 
D3
D4
D5
D6
D7
D8
(Study Discharge)a
Notes
Adverse Event Reporting
Monitor for Nonserious AEs
X
X
X
X
X
X
X
X
Nonserious AEs will be collected from the 
initiation of study treatment (Day 1) until 
3 days after the last dose of study treatment.
Monitor for SAEs
X
X
X
X
X
X
X
X
See note in screening procedures.
PK Assessments
See Table 9.5-1. An additional PK sample 
may be collected in the event of 
discontinuation due to an AE.
Serial Blood PK Sampling
X
X
X
X
X
X
X
X
See Section 9.5.
Clinical Drug Supplies
Randomize
X
Randomization will occur prior to study drug 
administration.
Apixaban Administration
X
X
See Section 7.
Other Assessments
Palatability Assessment
X
X
For both treatments. Palatability assessment 
will be completed immediately (within 
5 minutes) after administration of the 
apixaban 0.5-mg tablet and 0.1-mg sprinkle
capsule dosages. Refer to Appendix 6.
a Evaluations performed prior to study discharge or for participants who are prematurely discontinued. 
AE = adverse event; 
aPTT = activated partial thromboplastin time; 
D = Day; 
ECG = electrocardiogram; 
INR = international normalized ratio; 
PK = pharmacokinetic; PT = prothrombin time; SAE = serious adverse event
Date: 21-Mar-2018
10
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
In the event multiple procedures are required at a single time point, the 12-lead electrocardiogram 
(ECG) may be obtained up to 15 minutes earlier, vital signs may be obtained up to 10 minutes 
earlier or later, and the clinical laboratory blood sample may be obtained up to 5 minutes earlier 
than the nominal time point, ensuring the pharmacokinetic (PK) samples can be collected on time.
For predose procedures, vital signs within 30 minutes of dose, 12-lead ECG within 45 minutes, 
and predose PK collected within 15 minutes of dose. Vital signs and 12-lead ECG measurements 
should be performed before clinical laboratory and PK blood samples are collected.
3
INTRODUCTION
Factor Xa (FXa) plays a pivotal role in the coagulation cascade at the junction of the intrinsic and 
extrinsic pathways of the coagulation system. Inhibition of FXa is expected to exert anticoagulant 
and antithrombotic effects by decreasing the conversion of prothrombin to active thrombin, 
thereby diminishing thrombin-mediated activation of the coagulation process, including fibrin 
formation and platelet activation. Apixaban is an orally active, selective, reversible inhibitor of 
FXa and is approved for prevention of venous thromboembolism in patients who have undergone 
elective knee or hip replacement surgery, for stroke prevention in nonvalvular atrial fibrillation, 
and for treatment of venous thromboembolism and prevention of recurrent venous 
thromboembolism [USPI1 and SmPC2].
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date: 21-Mar-2018
11
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
 
 
3.3
Benefit/Risk Assessment
Since this is not an efficacy treatment study, there is no direct benefit to the participants 
participating in this study other than contributing to the research of a product.
The potential risk to participants from apixaban in this study is expected to be minimal. Approved 
apixaban doses are 2.5 mg twice daily (BID) in venous thromboembolism prevention in orthopedic 
patients, 5 mg BID in atrial fibrillation, and 10 mg BID for 7 days followed by 5 mg BID in venous 
thromboembolism treatment. In healthy participants, single and multiple oral doses of apixaban up 
to 25 mg BID for 7 days and 50 mg once daily for 3 days were well-tolerated. In this study, single 
2.5-mg doses of apixaban will be administered under medical supervision; each single dose will 
be separated by a washout period of at least 4 days. To ensure safety, participants with potential 
risk factors for bleeding will be excluded; this includes any history or evidence of abnormal 
bleeding or coagulation disorders, intracranial hemorrhage, or abnormal bleeding or coagulation 
disorders in a first degree relative.
Apixaban did not directly impair fertility or early embryonic development in rats and was not 
teratogenic in mice, rats, or rabbits at area under the concentration-time curve (AUC) multiples 
≤6.9 × the human AUC at 20 mg (10 mg BID). However, the reproductive risk of apixaban has 
not been evaluated in humans. Therefore, women of childbearing potential (WOCBP) who are 
unwilling or unable to use an acceptable method of contraception (Appendix 4) to avoid pregnancy 
for at least 4 weeks prior to dosing, during the study, and 33 days after the last dose of study 
treatment in such a manner that the risk of pregnancy is minimized will be excluded. In addition, 
male participants must agree to use an acceptable method of contraception during the entire study 
and for 93 days after the last dose. Male participants must not donate sperm during the entire study 
and for 93 days after the last dose.
Date: 21-Mar-2018
12
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
4
OBJECTIVES AND ENDPOINTS
Table 4-1:
Objectives and Endpoints
Objectives
Endpoints
Primary

To assess the bioavailability of apixaban 0.1-mg sprinkle
capsules relative to apixaban 0.5-mg tablets, both 
administered orally in healthy participants

Cmax, AUC(INF), AUC(0-T)
Secondary

To assess the safety and tolerability of apixaban

To assess the PK of apixaban 0.1-mg sprinkle capsules

To assess the PK of apixaban 0.5-mg tablets

Incidence of nonserious AEs, SAEs, and 
AEs leading to discontinuation; and results 
of vital signs, 12-lead ECGs, physical 
examinations, and clinical laboratory tests

Tmax, T-HALF, Frel
 
0.1-mg sprinkle capsules
5
STUDY DESIGN
5.1
Overall Design
This is a Phase 1, open-label, randomized, 2-period, 2-treatment crossover study in healthy 
participants. Healthy male or female participants as determined by medical history, physical 
examination, vital signs, 12-lead ECG, and clinical laboratory tests will be eligible to participate 
in the study. Participants will undergo screening evaluations to determine eligibility within 28 days 
prior to study treatment administration. On Day -1, participants will enter the clinical facility and 
be confined for the duration of the study, until discharge on Day 8. Prior to dosing on Day 1 of 
Period 1, participants will be randomly assigned to 1 of 2 treatment sequences (AB or BA, where 
Treatment A is 5 × 0.5-mg apixaban tablets and Treatment B is 25 × 0.1-mg apixaban sprinkle 
capsules) in a 1:1 ratio. Participants will receive a single oral dose of apixaban on Days 1 and 5. 
There will be a 4-day washout period between doses. Treatments A and B will be prepared in the 
pharmacy.
The study design schematic is presented in Figure 5.1-1.
Date: 21-Mar-2018
13
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Figure 5.1-1:
Study Design Schematic
D = Study Discharge; E = Enrollment; R = Randomization; S = Screening; Treatment A = 5 0.5-mg apixaban 
tablets; Treatment B = 25 0.1-mg apixaban sprinkle capsules; W = Washout
Physical examinations, vital sign measurements, 12-lead ECG, and clinical laboratory evaluations 
will be performed at selected times throughout the study. Participants will be closely monitored 
for adverse events (AEs) throughout the study. Blood samples will be collected for up to 72 hours 
after study drug administration for PK analysis. Approximately 240 mL of blood will be drawn 
from each participant during the study.
Participants will complete a palatability assessment (Appendix 6) immediately (within 5 minutes) 
after administration of the apixaban 0.5-mg tablet and 0.1-mg sprinkle capsule dosages, on both 
Day 1 and Day 5.
5.1.1
Data Monitoring Committee and Other External Committees
Not applicable.
5.2
Number of Participants
Sample size determination is discussed in Section 10.1. Approximately 30 participants 
(15 participants per treatment arm) are expected to be treated for this study in order to achieve 
approximately 28 evaluable participants (Section 10.2).
5.3
End of Study Definition
The start of the trial is defined as first visit for the first participant screened. End of trial is defined 
as the date of the last health status follow-up contact made to a participant discharged from the 
study. Study completion is defined as the final date on which data for the primary endpoint was or 
is expected to be collected, if this is not the same.
The approximate duration of this study will be 36 days, including a 28-day screening period.
 
 
 
Date: 21-Mar-2018
14
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
 
 
 
 
6
STUDY POPULATION
For entry into the study, the following criteria MUST be met prior to dosing on Day 1. No 
exceptions will be granted.
6.1
Inclusion Criteria
1) Signed Written Informed Consent
a) The signed informed consent form.
2) Type of Participant and Target Disease Characteristics
a) Healthy participants as determined by no clinically significant deviation from normal in 
medical history, physical examination, 12-lead ECGs, vital signs, and clinical laboratory 
tests including coagulation parameters.
b) Body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive. Body mass index = weight 
(kg)/[height(m)]2.
c) Participant Re-enrollment: This study permits the re-enrollment of a participant who has 
discontinued the study as a pretreatment failure (ie, has not been treated). If re-enrolled, 
the participant must be re-consented if outside of screening window (along with 
verification of eligibility).
3) Age and Reproductive Status
a) Males and Females, ages 18 to 45 years, inclusive.
b) Women of childbearing potential must have a negative quantitative serum pregnancy test 
(minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 
approximately 24 hours prior to the start of study treatment. Serum pregnancy tests will be 
performed at screening and Day -1.
c) Women must not be breastfeeding.
d) Women of childbearing potential must agree to follow instructions for method(s) of 
contraception for the duration of treatment with study treatment apixaban plus 5 half-lives 
of study treatment apixaban (~3 days) plus 30 days (duration of ovulatory cycle) for a total 
of 33 days post-treatment completion (Appendix 4).
e) Males who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception (Appendix 4) for the duration of treatment with study treatment
apixaban plus 5 half-lives of study treatment apixaban (~3 days) plus 90 days (duration of 
sperm turnover) for a total of 93 days post-treatment completion. In addition, male 
participants must be willing to refrain from sperm donation during this time. 
Date: 21-Mar-2018
15
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
f)
Azoospermic males are exempt from contraceptive requirements. Women of childbearing 
potential who are continuously not heterosexually active are also exempt from 
contraceptive requirements, and still must undergo pregnancy testing as described in this 
section.
Investigators shall counsel WOCBP and male participants who are sexually active with WOCBP
on the importance of pregnancy prevention and the implications of an unexpected pregnancy. 
Investigators shall advise on the use of highly effective methods of contraception, (Appendix 4)
which have a failure rate of < 1% when used consistently and correctly.
6.2
Exclusion Criteria
1) Medical Conditions
a) Any significant acute or chronic medical illness.
b) History of chronic headaches, defined as occurring 15 days or more a month, over the 
previous 3 months.
c) History of orthostatic instability or recurrent dizziness.
d) History of gastroesophageal reflux disease, dyspepsia, protracted nausea, or chronic 
diarrhea.
e) History of cholecystectomy.
f)
History of colitis.
g) History of upper gastrointestinal ulcer disease within 6 months, or current symptomatic or 
recent (within 3 months of dosing) gastrointestinal disease and gastrointestinal bleeding.
h) History of Gilbert’s Syndrome.
i)
Any major surgery within 4 weeks of dosing, or planned within 2 weeks after completion 
of the study.
j)
Any gastrointestinal surgery that could impact upon the absorption of study treatment.
k) Donation of blood to a blood bank or in a clinical study (except a screening visit or 
follow-up visit) within 4 weeks of study treatment administration (within 2 weeks for 
plasma only).
l)
Blood transfusion within 4 weeks of study treatment administration.
m) Inability to tolerate oral medication.
n) Inability to be venipunctured and/or tolerate venous access.
o) Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, 
pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 
6 months prior to study treatment administration.
p) Recent (within 6 months of study treatment administration) drug or alcohol abuse as 
defined in Diagnostic and Statistical Manual for Mental Disorders (DSM) IV, Diagnostic 
Criteria for Drug and Alcohol Abuse (Appendix 5).
q) History or evidence of abnormal bleeding or coagulation disorders, hypermenorrhea, 
intracranial hemorrhage, or abnormal bleeding or coagulation disorders. This includes a 
family history of bleeding diathesis in a first degree relative (eg, hemophilia).
r)
History of head injury in the last 2 years, intracranial tumor or aneurysm or known 
abdominal aneurysm, hemorrhoids with rectal bleeding.
Date: 21-Mar-2018
16
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
s) Any other sound medical, psychiatric and/or social reason as determined by the 
investigator.
2) Prior/Concomitant Therapy
a) Inability to comply with restrictions and prohibited treatments as listed in Section 7.7.1.
3) Physical and Laboratory Test Findings
a) Evidence of organ dysfunction or any clinically significant deviation from normal in 
physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations 
beyond what is consistent with the target population. See Section 6.4.1 for retesting 
information.
b) Sitting blood pressure: systolic blood pressure < 90 mmHg or > 140 mmHg or diastolic 
blood pressure < 50 mmHg or > 90 mmHg, confirmed by repeat.
c) Any of the following on 12-lead ECG prior to study treatment administration, confirmed 
by repeat:
i)
Heart rate < 50 beats per minute on both 12-lead ECG and while measuring vital 
signs
ii)
PR 210 msec
iii)
QRS 120 msec
iv)
QT 500 msec
v)
Fridericia’s corrected QT interval (QTcF) 450 msec
d) Any of the following clinical laboratory test results outside of the ranges specified below 
prior to study treatment administration, confirmed by repeat:
i)
Platelet count < lower limit of normal (LLN)
ii)
Activated partial thromboplastin time (aPTT) > upper limit of normal (ULN)
iii)
Prothrombin time (PT) > ULN
iv)
International normalized ratio (INR) > ULN
v)
Alanine aminotransferase (ALT) > ULN
vi)
Aspartate aminotransferase (AST) > ULN
vii)
Total bilirubin > ULN
viii) Serum creatinine 1.5 mg/dL
ix)
Hemoglobin < lower limit of normal (LLN)
x)
Hematocrit < LLN
xi)
Creatine kinase > 4 times the ULN
xii)
Uric acid > ULN
e) Positive urine screen for drugs of abuse including cotinine and alcohol.
f)
Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or human 
immunodeficiency virus (HIV)-1 and -2 antibody.
4) Allergies and Adverse Drug Reaction
a) History of allergy to apixaban, FXa inhibitors, or related compounds.
b) History of any significant drug allergy (such as anaphylaxis or hepatotoxicity).
Date: 21-Mar-2018
17
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
c) History of any adverse reaction to anticoagulants or antiplatelet agents that resulted in 
excessive bleeding requiring medication intervention.
5) Other Exclusion Criteria
a) Prisoners or participants who are involuntarily incarcerated. (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a participant. Strict conditions apply and Bristol-Myers Squibb (BMS) approval is 
required.
b) Participants who are compulsorily detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness.
c) Inability to comply with restrictions and prohibited activities/treatments as listed in 
Section 6.3.
Eligibility criteria for this study have been carefully considered to ensure the safety of the study 
participants and that the results of the study can be used. It is imperative that participants fully 
meet all eligibility criteria.
6.3
Lifestyle Restrictions
6.3.1
Meals and Dietary Restrictions
1) Participants are not permitted to consume any food or beverages containing grapefruit or other 
citrus fruit or citrus juice from 3 days prior to Day -1 through the duration of the study.
2) Participants may not drink water 1 hour before and after study treatment administration except 
with dosing. Water may be consumed ad libitum at other times.
3) Participants are required to fast (nothing to eat or drink except water) for 8 hours prior to and 
until 4 hours after study treatment administration on Days 1 and 5. 
4) On dosing days, a standard lunch will be served approximately 4 hours postdose. A standard 
dinner will be served approximately 8 hours postdose. A standard light snack will be served 
approximately 12 hours postdose. Meal content must be identical on Days 1 and 5. 
5) On days other than dosing, a standard breakfast, lunch, dinner, and light snack will be served. 
The food content of meals may vary during the washout period.
6.3.2
Caffeine, Alcohol and Tobacco
1) Participants are not permitted to consume caffeine-containing beverages from 3 days prior to 
the first dose until study discharge.
2) Participants are not permitted to consume alcohol-containing beverages from 3 days prior to 
the first dose until study discharge.
3) Tobacco or nicotine-containing products are not permitted throughout the study (see 
Section 6.2 Medical Conditions).
6.3.3
Activity
1) Participants are to refrain from strenuous exercise, contact sports, and sunbathing from at least 
3 day(s) prior to the first dose until study discharge.
2) Participants are required to remain in the clinical facility from Day -1 until study discharge. 
Date: 21-Mar-2018
18
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
3) Participants should maintain an upright (seated or standing) position for at least 4 hours 
postdose on Days 1 and 5. Participants should remain under direct observation by study staff 
during these times.
6.4
Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomized in the study. A minimal set of screen failure information is required 
to ensure transparent reporting of screen failure participants, to meet the Consolidated Standards 
of Reporting Trials (CONSORT) publishing requirements, and to respond to queries from 
regulatory authorities. Minimal information includes date of consent, demography, screen failure 
details, eligibility criteria, and any serious AEs (SAEs).
6.4.1
Retesting During Screening or Lead-In Period
Participant Re-enrollment: This study permits the re-enrollment of a participant who has 
discontinued the study as a pretreatment failure (ie, participant has not been randomized/has not 
been treated). If re-enrolled, the participant must be re-consented.
Retesting of laboratory parameters and/or other assessments within any single screening or lead-in 
period will be permitted (in addition to any parameters that require a confirmatory value).
The most current result prior to randomization is the value by which study inclusion will be 
assessed, as it represents the participant’s most current clinical state.
Laboratory parameters and/or assessments that are included in Table 2-1, Screening Procedural 
Outline may be repeated in an effort to find all possible well-qualified participants. Consultation 
with the Medical Monitor may be needed to identify whether repeat testing of any particular 
parameter is clinically relevant.
7
TREATMENT
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo or 
medical device intended to be administered to a study participant according to the study 
randomization or treatment allocation.

Apixaban, 2.5 mg (5 0.5-mg tablets) (Investigational Product [IP])

Apixaban, 2.5 mg (25 0.1-mg sprinkle capsules) (IP)
Study 
treatment
includes 
both 
Investigational 
[Medicinal] 
Product 
(IP/IMP) 
and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and can consist of the following:

All products, active or placebo, being tested or used as a comparator in a clinical trial

Study required premedication

Other drugs administered as part of the study that are critical to claims of efficacy 
(eg, background therapy, rescue medications)

Diagnostic agents: (such as glucose for glucose challenge) given as part of the protocol 
requirements must also be included in the dosing data collection
An IP, also known as IMP in some regions, is defined as a pharmaceutical form of an active 
substance or placebo being tested or used as a reference in a clinical study, including products 
Date: 21-Mar-2018
19
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
already with a marketing authorization but used or assembled (formulated or packaged) differently 
than the authorized form, or used for an unauthorized indication, or when used to gain further 
information about the authorized form.
Other medications used as support or escape medication for preventative, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as non-IPs.
Date: 21-Mar-2018
20
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Table 7-1:
Study treatments for CV185687
Product Description / 
Class and Dosage Form
Potency
IP/Non-IMP
Blinded or 
Open Label
Packaging/Appearance
Storage Conditions
(per label)
Apixaban
(BMS-562247)
Film-Coated Tablet
0.5 mg
IP
Open label
Tablets in a bottle
Refer to label on 
container
Apixaban
(BMS-562247)
Sprinkle Capsule
0.1 mg
IP
Open label
Capsules in a bottle
Refer to label on 
container
Note: Procedures for preparation and administration of the apixaban 0.5-mg tablet and 0.1-mg sprinkle capsule dosages will be provided in the pharmacy manual.
Date: 21-Mar-2018
21
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
7.1
Treatments Administered
The selection and timing of dose for each participant is as follows:
Table 7.1-1:
Selection and Timing of Dose
Study Treatment
Unit Dose 
Strength(s)/Dosage Level(s)
Dosage Formulation
Frequency of Administration
Route of 
Administration
Apixaban 
0.5-mg tablets
(Treatment A)
5 0.5 mg
Single dose on Day 1 or Day 5
Oral
Apixaban
0.1-mg sprinkle capsules
(Treatment B)
25 0.1 mg
Single dose on Day 1 or Day 5
Oral
In the morning on Days 1 and 5, each participant will receive a single oral dose of apixaban after 
fasting for at least 8 hours. Participants will fast for at least 4 hours after study treatment 
administration on Days 1 and 5.
Treatment A will be administered as 5 0.5-mg apixaban tablets; the tablets will be dissolved in 
water, and the entire apixaban solution must be consumed. Procedures for preparation and 
administration of the 5 0.5-mg apixaban tablets will be provided in the pharmacy manual.
Treatment B will be administered as 25 0.1-mg apixaban sprinkle capsules; the capsules will be 
opened and contents will be emptied into water, and the entire apixaban solution must be 
consumed. Procedures for preparation and administration of the 25 0.1-mg apixaban sprinkle 
capsules will be provided in the pharmacy manual.
Treatments A and B will be prepared in the pharmacy. Preparation and administration should occur 
within the established stability window. Additional details are available in the pharmacy manual.
The time of dose administration will be called “0” hour.
Restrictions related to food and fluid intake are described in Section 6.3.
7.2
Method of Treatment Assignment
Participants will be randomized in a 1:1 ratio to 1 of 2 treatment sequences according to a 
computer-generated randomization scheme prepared by PPD. 
Study treatment will be dispensed at the study visits as listed in Schedule of Activities (Section 2). 
Enrolled participants, including those not dosed, will be assigned sequential participant numbers 
starting with 00001, (eg, 00001, 00002, 00003.... 00010). Those enrolled participants meeting 
inclusion and exclusion criteria will be eligible to be randomized. Randomization numbers will be 
assigned prior to dosing.
Participants will not be replaced if they are discontinued from the study secondary to an AE unless 
the AE can be determined to be unrelated to treatment. The Sponsor (or designee) may replace 
Date: 21-Mar-2018
22
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
participants for other reasons. If a participant is replaced after dosing then the replacement 
participant will be assigned the original participant’s number plus 100. The replacement participant
will receive the same treatments as the participant being replaced but a new randomization number 
will be assigned to him or her. For example, Participant 4 would be replaced by Participant 104.
7.3
Blinding
This is an open-label study, blinding procedures are not applicable.
7.4
Dosage Modification
Modifications of the dosage schedule may not be made without a written amendment to the 
protocol.
7.5
Preparation/Handling/Storage/Accountability
The IP should be stored in a secure area according to local regulations. It is the responsibility of 
the investigator to ensure that IP is only dispensed to study participants. The IP must be dispensed 
only from official study sites by authorized personnel according to local regulations.
The product storage manager should ensure that the study treatment is stored in accordance with 
the environmental conditions (temperature, light, and humidity) as determined by BMS. If 
concerns regarding the quality or appearance of the study treatment arise, the study treatment
should not be dispensed and contact BMS immediately.
Study treatment not supplied by BMS will be stored in accordance with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained that 
includes all processes required to ensure drug is accurately administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes (eg, required diluents, administration sets).
Further guidance and information for final disposition of unused study treatment are provided in 
Appendix 2 and as specified by the study team.  
7.5.1
Retained Samples for Bioavailability / Bioequivalence
Not applicable.
7.6
Treatment Compliance
Study drug will be administered in the clinical facility. After administration of apixaban, including 
rinses if applicable, an examination of the oral cavity is required to verify that a participant has 
swallowed the entire apixaban solution. A mouth check should be performed after the final amount 
of apixaban solution has been taken. The participant should drink the entire apixaban solution 
(Treatment A or B) including any rinses as appropriate.
Date: 21-Mar-2018
23
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
 
 
 
 
 
 
 
 
 
 
 
7.8
Treatment After the End of the Study
At the end of the study, BMS will not continue to provide BMS supplied study treatment to 
participants/investigators unless BMS chooses to extend the study. The investigator should ensure 
that the participant receives appropriate standard of care to treat the condition under study.
8
DISCONTINUATION CRITERIA
8.1
Discontinuation from Study Treatment
Participants MUST discontinue IP (and non-IP at the discretion of the investigator) for any of the 
following reasons:

Participant’s request to stop study treatment. Participants who request to discontinue study 
treatment will remain in the study and must continue to be followed for protocol specified 
follow-up procedures. The only exception to this is when a participant specifically withdraws 
consent for any further contact with him/her or persons previously authorized by participant to 
provide this information

Any clinical AE, laboratory abnormality or intercurrent illness which, in the opinion of the 
investigator, indicates that continued participation in the study is not in the best interest of the 
participant

Termination of the study by BMS
Date: 21-Mar-2018
24
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban

Loss of ability to freely provide consent through imprisonment or involuntarily incarceration 
for treatment of either a psychiatric or physical (eg, infectious disease) illness. (Note: Under 
specific circumstances, a participant who has been imprisoned may be permitted to continue 
as a participant. Strict conditions apply and BMS approval is required.)

Inability to comply with protocol

Discretion of the investigator
Discontinuation of the study treatment for abnormal liver tests should be considered by the 
investigator when a participant meets one of the conditions outlined in Section 9.2.7, or if the 
investigator believes that it is in best interest of the participant.
Refer to the Schedule of Activities for data to be collected at the time of treatment discontinuation 
and follow-up and for any further evaluations that can be completed (Section 2).
In the case of pregnancy, the investigator must immediately notify the BMS Medical 
Monitor/designee of this event. In the event a normal healthy female participant becomes pregnant 
during a clinical trial, the study treatment must be discontinued immediately. In most cases, the 
study treatment will be permanently discontinued in an appropriate manner (eg, dose tapering if 
necessary for participant safety). Please call the BMS Medical Monitor within 24 hours of 
awareness of the pregnancy. If the investigator determines a possible favorable benefit/risk ratio 
that warrants continuation of study treatment, a discussion between the investigator and the BMS 
Medical Monitor/designee must occur.
All participants who discontinue study treatment should comply with protocol specified follow-up 
procedures as outlined in Section 2. The only exception to this requirement is when a participant
withdraws consent for all study procedures including post-treatment study follow-up or loses the 
ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either 
a psychiatric or physical illness).
If study treatment is discontinued prior to the participant’s completion of the study, the reason for 
the discontinuation must be documented in the participant’s medical records and entered on the 
appropriate CRF page.
8.1.1
Post Study Treatment Study Follow-up
Participants who discontinue study treatment may continue to be followed.
8.2
Discontinuation from the Study
Participants who request to discontinue study treatment will remain in the study and must continue 
to be followed for protocol specified follow-up procedures. The only exception to this is when a 
participant specifically withdraws consent for any further contact with him/her or persons 
previously authorized by participant to provide this information. 

Participants should notify the investigator of the decision to withdraw consent from future 
follow-up in writing, whenever possible.

The withdrawal of consent should be explained in detail in the medical records by the 
investigator, as to whether the withdrawal is from further treatment with study treatment only 
Date: 21-Mar-2018
25
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
or also from study procedures and/or post treatment study follow-up, and entered on the 
appropriate CRF page.

In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly available information should be used to determine vital status only as appropriately 
directed in accordance with local law.

If the participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.
8.3
Lost to Follow-Up

All reasonable efforts must be made to locate participants to determine and report their ongoing 
status. This includes follow-up with persons authorized by the participant.

Lost to follow-up is defined by the inability to reach the participant after a minimum of three
documented phone calls, faxes, or emails as well as lack of response by participant to one 
registered mail letter. All attempts should be documented in the participant’s medical records.

If it is determined that the participant has died, the site will use permissible local methods to 
obtain date and cause of death.

If investigator’s use of third-party representative to assist in the follow-up portion of the study 
has been included in the participant’s informed consent, then the investigator may use a 
Sponsor retained third-party representative to assist site staff with obtaining participant’s 
contact information or other public vital status data necessary to complete the follow-up 
portion of the study. 

The site staff and representative will consult publicly available sources, such as public health 
registries and databases, in order to obtain updated contact information.

If after all attempts, the participant remains lost to follow-up, then the last known alive date as 
determined by the investigator should be reported and documented in the participant’s medical 
records.
9
STUDY ASSESSMENTS AND PROCEDURES

Study procedures and timing are summarized in the Schedule of Activities (Section 2). 

Protocol waivers or exemptions are not allowed.

All immediate safety concerns must be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.

Adherence to the study design requirements, including those specified in the Schedule of 
Activities, is essential and required for study conduct.

All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria before randomization. The investigator will maintain a 
screening log to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.

Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of informed consent may be utilized for screening or 
baseline purposes provided the procedure meets the protocol-defined criteria and has been 
performed within the timeframe defined in the Schedule of Activities.
Date: 21-Mar-2018
26
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
9.1
Efficacy Assessments
Not applicable.
9.2
Adverse Events
The definitions of an AE or SAE can be found in Appendix 3.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative). 
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study treatment or the study, or that caused the participant to 
discontinue before completing the study. 
Contacts for SAE reporting specified in Appendix 3
9.2.1
Time Period and Frequency for Collecting AE and SAE Information
The collection of nonserious AE information should begin at initiation of study treatment until the 
time points specified in the Schedule of Activities (Section 2). Nonserious AE information should 
also be collected from the start of a placebo lead-in period or other observational period intended 
to establish a baseline status for the participants.
Sections 5.6.1 and 5.6.2 in the IB represent the Reference Safety Information to determine 
expectedness of SAEs for expedited reporting. Following the participant’s written consent to 
participate in the study, all SAEs, whether related or not related to study drug, must be collected, 
including those thought to be associated with protocol-specified procedures.
All SAEs must be collected that occur during the screening period and within 30 days of 
discontinuation of dosing.
The investigator must report any SAE that occurs after these time periods and that is believed to 
be related to study drug or protocol-specified procedure.

Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the CRF section.

All SAEs will be recorded and reported to Sponsor or designee within 24 hours, as indicated 
in Appendix 3. 

The investigator will submit any updated SAE data to the Sponsor within 24 hours of this being 
available.
Investigators are not obligated to actively seek AEs or SAEs in former study participants. 
However, if the investigator learns of any SAE, including a death, at any time after a participant 
has been discharged from the study, and he/she considers the event reasonably related to the study 
treatment or study participation, the investigator must promptly notify the Sponsor.
The method of evaluating, and assessing causality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in Appendix 3.
Date: 21-Mar-2018
27
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
9.2.2
Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a participant. Care should be taken not to introduce bias when 
collecting AE and/or SAEs. Inquiry about specific AEs should be guided by clinical judgement in 
the context of known AEs, when appropriate for the program or protocol.
9.2.3
Follow-up of AEs and SAEs

Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Appendix 3).

Follow-up is also required for nonserious AEs that cause interruption or discontinuation of 
study treatment and for those present at the end of study treatment as appropriate.
All identified nonserious AEs must be recorded and described on the nonserious AE page of 
the CRF (paper or electronic). Completion of supplemental CRFs may be requested for AEs
and/or laboratory abnormalities that are reported/identified during the course of the study.
All SAEs will be followed until resolution, until the condition stabilizes, until the event is 
otherwise explained, or until the participant is lost to follow-up (as defined in Section 8.3).
Further information on follow-up procedures is given in Appendix 3.
9.2.4
Regulatory Reporting Requirements for SAEs

Prompt notification by the investigator to the Sponsor of SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
product under clinical investigation are met.

An investigator who receives an investigator safety report describing SAEs or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will file it along with 
the IB and will notify the Institutional Review Board/Independent Ethics Committee, if 
appropriate according to local requirements.
Sponsor or designee will be reporting AEs to regulatory authorities and ethics committees 
according to local applicable laws including European Directive 2001/20/EC and US Food and 
Drug Administration (FDA) Title 21 of the Code of Federal Regulations, Parts 312 and 320. A 
SUSAR (Suspected, Unexpected Serious Adverse Reaction) is a subset of SAEs and will be 
reported to the appropriate regulatory authorities and investigators following local and global 
guidelines and requirements.
9.2.5
Pregnancy
If, following initiation of the study treatment, it is subsequently discovered that a participant is 
pregnant or may have been pregnant at the time of study exposure, including during at least 
5 half-lives after product administration, the investigator must immediately notify the BMS 
Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillance Form 
to BMS Designee within 24 hours of awareness of the event and in accordance with SAE reporting 
procedures described in Appendix 3.
Date: 21-Mar-2018
28
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
In most cases, the study treatment will be permanently discontinued in an appropriate manner 
(eg, dose tapering if necessary for participant safety). Please call the BMS Medical Monitor within 
24 hours of awareness of the pregnancy.
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring information must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
Sponsor or designee. In order for Sponsor or designee to collect any pregnancy surveillance 
information from the female partner, the female partner must sign an informed consent form for 
disclosure of this information. Information on this pregnancy will be collected on the Pregnancy 
Surveillance Form.
9.2.6
Laboratory Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form electronic, as appropriate. Paper forms are only intended as a back-up 
option when the electronic system is not functioning.

Any laboratory test result that is clinically significant or meets the definition of an SAE 

Any laboratory test result abnormality that required the participant to have study treatment
discontinued or interrupted

Any laboratory test result abnormality that required the participant to receive specific 
corrective therapy
It is expected that wherever possible, the clinical rather than laboratory term would be used by the 
reporting investigator (eg, anemia versus low hemoglobin value).
9.2.7
Potential Drug-Induced Liver Injury (DILI)
Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should 
occur prior to the reporting of a potential drug-induced liver injury (DILI) event. All occurrences
of potential DILIs, meeting the defined criteria, must be reported as SAEs (see Section 9.2 and 
Appendix 3 for reporting details).
Potential DILI is defined as: 
1) Aminotransaminases (ALT or AST) elevation > 3 times ULN
AND
2) Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline 
phosphatase),
AND
3) No other immediately apparent possible causes of aminotransaminases elevation and 
hyperbilirubinemia, including, but not limited to, viral hepatitis, pre-existing chronic or acute 
liver disease, or the administration of other drug(s) known to be hepatotoxic.
Date: 21-Mar-2018
29
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
9.2.8
Other Safety Considerations
Any significant worsening noted during interim or final physical examinations, 12-lead ECGs, 
X-ray filming, any other potential safety assessment required or not required by protocol should 
also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.
9.3
Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product that 
is considered both excessive and medically important. All occurrences of overdose must be 
reported as an SAE (see Section 9.2).
For this study, any dose of apixaban greater than 2.5 mg within a 24-hour time period will be 
considered an overdose.
9.4
Safety
Planned time points for all safety assessments are listed in the Schedule of Activities (Section 2).
Only data for the procedures and assessments specified in this protocol should be submitted to 
BMS or designee on a CRF. Additional procedures and assessments may be performed as part of 
standard of care; however, data for these assessments should remain in the participant’s medical 
record and should not be provided to BMS, unless specifically requested by BMS.
9.4.1
Physical Examinations
Refer to Schedule of Activities (Section 2).
9.4.1.1
Rash Photography
Starting on Day -1, standard baseline medical dermatology photographs of areas affected by rash 
will be taken. If there are any changes with the affected areas or new areas of rash are detected, 
additional photographs will be obtained. Photographs will not be needed if there is no evidence of 
rash or no change in the affected areas.
9.4.2
Vital Signs
Refer to Schedule of Activities (Section 2).
9.4.3
Electrocardiograms
Refer to Schedule of Activities (Section 2).
9.4.4
Clinical Safety Laboratory Assessments
Investigators must document their review of each laboratory safety report.
A local laboratory will perform the analyses and will provide reference ranges for these tests.
Results of clinical laboratory tests performed on Day -1 and Day 4 must be available prior to 
dosing on Days 1 and 5, respectively.
Date: 21-Mar-2018
30
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Hematology
Hemoglobin
Hematocrit
Total leukocyte count, including differential
Platelet count
Coagulation (at screening, Day -1, Day 4, and Day 7)
aPTT
INR
PT
Serum Chemistry
AST
ALT
Total bilirubin
Direct bilirubin (reflex if elevated total 
bilirubin)
Alkaline phosphatase
Lactate dehydrogenase
Creatinine
Blood Urea Nitrogen
Uric acid (screening only)
Fasting glucose
Total Protein
Albumin
Sodium
Potassium
Chloride
Calcium
Phosphorus
Creatine kinase (screening only)
Urinalysis
Protein
Glucose
Blood
Leukocyte esterase
Specific gravity
pH
Microscopic examination of the sediment if blood is detected on the initial analysis
Serology
Serum hepatitis C antibody, hepatitis B surface antigen, HIV-1 or -2 antibody (screening only)
Other Analyses
Urine for drugs of abuse including cotinine and alcohol (screening and Day -1)
Serum pregnancy test (women only: at screening, Day -1, Day 4, and Day 7)
Serum follicle-stimulating hormone (postmenopausal women only; screening)
9.4.5
Suicidal Risk Monitoring
Not applicable.
9.4.6
Imaging Safety Assessment
Not applicable.
Date: 21-Mar-2018
31
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
9.4.7
Physical Measurements
Refer to Schedule of Activities (Section 2).
9.4.8
Medical History
Refer to Schedule of Activities (Section 2).
9.4.9
Adverse Event Monitoring
Participants will be closely monitored throughout the study for AEs and will not be discharged 
from the study until the investigator has determined that AEs have either completely resolved or 
are not of clinical significance.
9.5
Pharmacokinetics
Pharmacokinetics of apixaban will be derived from plasma concentration versus time. The PK
parameters to be assessed include the following to the extent that data permit their calculation:
Cmax
Maximum observed plasma concentration
Tmax
Time of maximum observed plasma concentration
AUC(0-T)
Area under the plasma concentration-time curve from time zero to time 
of last quantifiable concentration
AUC(INF)
Area under the plasma concentration-time curve from time zero 
extrapolated to infinite time
T-HALF
Terminal plasma half-life
Frel
Relative bioavailability
Individual participant PK parameter values will be derived by noncompartmental methods by a 
validated PK analysis program. Actual times will be used for the analyses. Table 9.5-1 lists the 
sampling schedule to be followed for the assessment of apixaban PK. Further details of blood 
collection and processing will be provided to the site in the procedure manual.
Date: 21-Mar-2018
32
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Table 9.5-1:
Pharmacokinetic Sampling Schedule
Study Day of 
Sample Collection
Event
Time
(Relative To Dosing)
Hour: Min
PK Blood Sample for 
Apixaban
1 and 5
predose
00:00
X
00:15
X
00:30
X
01:00
X
02:00
X
03:00
X
04:00
X
05:00
X
06:00
X
09:00
X
12:00
X
2 and 6
24:00
X
36:00
X
3 and 7
48:00
X
60:00
X
4 and 8
72:00
X
The plasma samples will be analyzed for apixaban by a validated liquid chromatography tandem 
mass spectrometry assay. The lower limit of quantification of apixaban is 1 ng/mL. In addition, 
plasma samples will be archived for potential metabolite analysis, if the need arises and to the 
extent possible.
The Study Director should be consulted before any requests for PK re-analysis.
Detailed instructions for the pharmacokinetic blood collection, labeling, processing, storage, and 
shipping will be provided to the site in the procedure manual.
9.6
Pharmacodynamics
Pharmacodynamic parameters are not evaluated in this study.
9.7
Pharmacogenomics
Not applicable.
Date: 21-Mar-2018
33
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
9.8.1
Additional Research Collection
This protocol will include residual sample storage for additional research.
Additional research is required for all study participants, except where prohibited by IRBs/ethics 
committees, or academic/institutional requirements. Where one or more of these exceptions 
occurs, participation in the additional research should be encouraged but will not be a condition of 
overall study participation.

If the IRB/ethics committees and site agree to the mandatory additional research retention 
and/or collection, then the study participant must agree to the mandatory additional research 
as a requirement for inclusion in the study.

If optional participation is permitted and approved, then the study participants may opt out of 
the additional research retention and/or collection.
This collection for additional research is intended to expand the translational R&D capability at 
BMS, and will support as yet undefined research aims that will advance our understanding of 
disease and options for treatment. It may also be used to support health authority requests for 
analysis, and advancement of pharmacodiagnostic development to better target drugs to the right 
patients. This may also include genetic/genomic exploration aimed at exploring disease pathways, 
progression and response to treatment etc. 
Sample Collection and Storage
All requests for access to samples or data for additional research will be vetted through a diverse 
committee of the study Sponsor’s senior leaders in Research and Development (or designee) to 
ensure the research supports appropriate and well-defined scientific research activities.
Residual plasma from PK collections (Table 9.8.1-1) will also be retained for additional research 
purposes.
 
The manager of these samples will ensure they are properly used throughout their usable life and 
will destroy the samples at the end of the scheduled storage period, no longer than fifteen (15) 
years after the end of the study or the maximum allowed by applicable law.
Transfers of samples by research Sponsor to third parties will be subject to the recipient’s 
agreement to establish similar storage procedures.
 
 
Further details of sample collection and processing will be provided to the site in the procedure 
manual.
Date: 21-Mar-2018
34
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Table 9.8.1-1:
Residual Sample Retention for Additional Research Schedule
Sample Type
Time points for which residual samples will be retained
Plasma PK
All
 
 
9.9
Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resource Utilization and Health Economics parameters will not be 
evaluated in this study.
10
STATISTICAL CONSIDERATIONS
10.1
Sample Size Determination 
The similarity of the bioavailability will be concluded if the 90% confidence interval (CI) for the 
ratio of geometric means of apixaban 0.1-mg sprinkle capsules relative to apixaban 0.5-mg tablets 
are wholly contained within 80% and 125% for Cmax and AUC. The following table shows the 
power provided with data from 28 PK evaluable participants based on different assumptions of 
difference between the bioavailability of apixaban 0.1-mg sprinkle capsules and apixaban 0.5-mg 
tablets.
True Geometric 
Mean Ratio
Power of 
Cmax
Power of 
AUC(0-T)
Power of 
AUC(INF)
Overall 
Power
1
99%
99%
99%
97%
1.02
99%
99%
99%
97%
1.04
98%
99%
99%
96%
1.06
96%
99%
99%
94%
1.08
91%
99%
99%
89%
1.1
83%
99%
99%
81%
As an example, if there is a 10% difference between the bioavailability of apixaban 0.1-mg sprinkle
capsules and apixaban 0.5-mg tablets, then data from 28 PK evaluable participants will provide 
approximately 83%, 99%, and 99% power to conclude similar bioavailability for Cmax, 
AUC(INF), and AUC(0-T), respectively. The overall power for this hypothesis is approximately 
81%. 
These calculations use the approach described by Diletti et al.6 and assume Cmax and AUC are 
log normally distributed with intra-subject coefficient of variation (CV%) of 18% for Cmax and 
Date: 21-Mar-2018
35
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
12% for AUC, as estimated from apixaban Study CV1851114 and Study CV1852927. To allow for 
possible dropouts, a total of 30 participants are planned to be randomized to obtain at least 
28 PK-evaluable participants.
10.2
Populations for Analyses
For purposes of analysis, the following populations are defined:
Population
Description
Enrolled
All participants who signed the informed consent
Randomized
All participants who are randomized to a sequence of treatments.
Treated
All participants who received at least 1 dose of study treatment. This 
population will be used for the safety analyses.
Pharmacokinetic
All participants who received at least 1 dose of study treatment and 
had any available concentration-time data. Pharmacokinetic listings 
and PK parameter calculations will be based on this population.
Evaluable PK
All participants who had adequate PK profiles for accurate estimation 
of PK parameters and had no protocol deviations considered to affect 
the PK assessments.
All available derived PK parameter values will be included in the PK 
data set and reported, but only participants with evaluable PK will be 
included in the summary statistics and statistical analysis.
10.3
Statistical Analyses
The statistical analysis plan will be developed and finalized before database lock and will describe 
the selection of participants to be included in the analyses, and procedures for accounting for 
missing, unused, and spurious data. Below is a summary of planned statistical analyses.
10.3.1
Demographics and Baseline Characteristics
Frequency distribution of gender, ethnicity, and race will be tabulated. Summary statistics for age, 
body weight, height, and BMI will be tabulated.
10.3.2
Efficacy Analyses
Not applicable.
Date: 21-Mar-2018
36
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
10.3.3
Safety Analyses
Endpoint
Statistical Analysis Methods
The occurrence of nonserious 
AEs, SAEs, AEs leading to 
discontinuation or death; results 
of clinical laboratory tests, vital 
sign measurements, 12-lead 
ECGs, and physical 
examinations; and marked 
abnormalities in clinical 
laboratory test results
All recorded AEs will be listed and tabulated by system 
organ class, preferred term, and treatment. Adverse events 
which occur on or after the first dose of study treatment, 
within 3 days after the last dose of study treatment for 
nonserious AEs, and 30 days after the last dose of study 
treatment for SAEs will be included in summary statistics. 
Adverse events leading to discontinuation or death will be 
listed. Vital sign measurements, 12-lead ECGs, and clinical 
laboratory test results will be listed. Any abnormal physical 
examination findings will be listed. The number and 
percentage of participants with marked clinical laboratory 
abnormalities will be summarized. Electrocardiogram 
recordings will be evaluated by the investigator and 
abnormalities, if present, will be listed.
10.3.4
Pharmacokinetic Analyses
Endpoint
Statistical Analysis Methods
Cmax, AUC(INF), 
and AUC(0-T) 
Analyses will be performed on the natural logarithms of Cmax, 
AUC(INF), and AUC(0-T) using linear mixed-effects model with 
treatment and period as fixed effects and measurements within participant 
as repeated measures. Point estimates and 90% CIs for treatment 
differences on the log scale derived from the model will be exponentiated 
to obtain estimates for ratios of geometric means and CIs on the original 
scale.
Summary statistics will be tabulated for all PK parameters by treatment. 
Geometric means and coefficient of variations will be presented for Cmax, 
AUC(INF), and AUC(0-T). Individual treatment ratios for PK parameters 
will be provided in listings and summarized. Plots of individual ratios, 
geometric least square mean ratios, and corresponding 90% CIs from the 
statistical analysis model will also be provided. In addition, the geometric 
mean ratios and corresponding 90% CIs of Cmax, AUC(INF), and 
AUC(0-T) will be presented in forest plots.
Tmax, T-HALF, 
and Frel
Summary statistics will be tabulated for all PK parameters by treatment. 
Arithmetic mean and standard deviation will be presented for T-HALF; 
median and range will be presented for Tmax. Individual Tmax 
differences will be provided in listings and summarized. Geometric means 
and coefficient of variations will be presented for Frel.
Date: 21-Mar-2018
37
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
10.3.5
Interim Analyses
Not applicable.
Date: 21-Mar-2018
38
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
 
 
 
 
 
 
 
 
Date: 21-Mar-2018
39
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
12
APPENDICES
Date: 21-Mar-2018
40
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
APPENDIX 1
ABBREVIATIONS AND TRADEMARKS
Term
Definition
AE
adverse event
ALT
alanine aminotransferase
aPTT
activated partial thromboplastin time
AST
aspartate aminotransferase
AUC
area under the plasma concentration-time curve
AUC(INF)
area under the plasma concentration-time curve from time zero 
extrapolated to infinite time
AUC(0-T)
area under the plasma concentration-time curve from time zero to the 
time of the last quantifiable concentration
BID
twice daily
BMI
body mass index
BMS
Bristol-Myers Squibb
CI
confidence interval
Cmax
maximum observed plasma concentration
CONSORT
Consolidated Standards of Reporting Trials
CRF
case report form, paper or electronic
DILI
drug-induced liver injury
DSM IV
Diagnostic and Statistical Manual of Mental Disorders (4th Edition)
ECG
electrocardiogram
F
bioavailability
FDA
US Food and Drug Administration
Frel
relative bioavailability
FXa
Factor Xa
HIV
human immunodeficiency virus
IB
Investigator Brochure
IEC
Independent Ethics Committee
IND
Investigational New Drug
IRB
Institutional Review Board
LLN
lower limit of normal
PK
pharmacokinetics
Date: 21-Mar-2018
41
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Term
Definition
PT
prothrombin time
SAE
serious adverse event
T-HALF
terminal plasma half-life
Tmax
time of maximum observed plasma concentration
ULN
upper limit of normal
WOCBP
women of childbearing potential
Date: 21-Mar-2018
42
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
APPENDIX 2
STUDY GOVERNANCE CONSIDERATIONS
The term ‘Participant’ is used in the protocol to refer to a person who has consented to participate 
in the clinical research study. The term ‘Subject’ used in the eCRF is intended to refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:

Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines Good Clinical Practice (GCP)

as defined by the International Council for Harmonisation (ICH)

in accordance with the ethical principles underlying European Union Directive 2001/20/EC

United States Code of Federal Regulations, Title 21, Part 50 (21CFR50) 

applicable local requirements
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the participant informed consent will receive approval/favorable opinion by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC), and regulatory authorities according to 
applicable local regulations prior to initiation of the study.
All potential serious breaches must be reported to Sponsor or designee immediately. A serious 
breach is a breach of the conditions and principles of GCP in connection with the study or the 
protocol, which is likely to affect, to a significant degree, the safety or physical or mental integrity 
of the subjects of the study or the scientific value of the study.
Personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.
This study will not use the services of study personnel where sanctions have been invoked or where 
there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, participant recruitment materials 
(eg, advertisements), and any other written information to be provided to subjects. The investigator 
or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product 
labeling information to be provided to subjects and any updates. 
The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safety reports, amendments, and administrative letters) according to 
regulatory requirements or institution procedures.
Date: 21-Mar-2018
43
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not implement any deviation or change to the protocol without prior 
review and documented approval/favorable opinion of an amendment from the IRB/IEC (and if 
applicable, also by local health authority) except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant approval/favorable opinion(s) the deviation or change will be submitted, as soon 
as possible to:

IRB/IEC

Regulatory Authority(ies), if applicable by local regulations (per national requirements)
Documentation of approval/favorable opinion signed by the chairperson or designee of the 
IRB(s)/IEC(s) and if applicable, also by local health authority must be sent to BMS.
If an amendment substantially alters the study design or increases the potential risk to the 
participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review 
and approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate health authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study.
INFORMED CONSENT PROCESS
Investigators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the participant volunteers to participate. 
Sponsor or designee will provide the investigator with an appropriate (ie, Global or Local) sample 
informed consent form which will include all elements required by ICH, GCP and applicable 
regulatory requirements. The sample informed consent form will adhere to the ethical principles 
that have their origin in the Declaration of Helsinki.
Date: 21-Mar-2018
44
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Investigators must:

Provide a copy of the consent form and written information about the study in the language in 
which the participant is most proficient prior to clinical study participation. The language must 
be non-technical and easily understood. 

Allow time necessary for participant or participant's legally acceptable representative to 
inquire about the details of the study.

Obtain an informed consent signed and personally dated by the participant or the participant's 
legally acceptable representative and by the person who conducted the informed consent 
discussion. 

Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent form 
and any other information to be provided to the subjects, prior to the beginning of the study, 
and after any revisions are completed for new information.
If informed consent is initially given by a participant’s legally acceptable representative or legal 
guardian, and the participant subsequently becomes capable of making and communicating his or 
her informed consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever important new information becomes available that is 
relevant to the participant's consent. The investigator, or a person designated by the investigator, 
should fully inform the participant or the participant's legally acceptable representative or legal 
guardian, of all pertinent aspects of the study and of any new information relevant to the 
participant's willingness to continue participation in the study. This communication should be 
documented. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF and, in the 
US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory authorities have direct 
access to participant records. 
For minors, according to local legislation, one or both parents or a legally acceptable representative 
must be informed of the study procedures and must sign the informed consent form approved for 
the study prior to clinical study participation. The explicit wish of a minor, who is capable of 
forming an opinion and assessing this information to refuse participation in, or to be withdrawn 
from, the clinical study at any time should be considered by the investigator. 
Minors who are judged to be of an age of reason must also give their written assent.
Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia) may 
only be enrolled in the study with the consent of a legally acceptable representative. The participant 
must also be informed about the nature of the study to the extent compatible with his or her 
understanding, and should this participant become capable, he or she should personally sign and 
date the consent form as soon as possible. The explicit wish of a participant who is unable to give 
his or her written consent, but who is capable of forming an opinion and assessing information to 
Date: 21-Mar-2018
45
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
refuse participation in, or to be withdrawn from, the clinical study at any time should be considered 
by the investigator.
The rights, safety, and well-being of the study subjects are the most important considerations and 
should prevail over interests of science and society.
SOURCE DOCUMENTS
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand-written on paper or entered 
electronically. If source data are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol required assessments, and/or drug accountability 
records).
When paper records from such systems are used in place of electronic format to perform regulated 
activities, such paper records should be certified copies. A certified copy consists of a copy of 
original information that has been verified, as indicated by a dated signature, as an exact copy 
having all of the same attributes and information as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (whether supplied by BMS, its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for review at the request of BMS/designee 
or a Health Authority.
Date: 21-Mar-2018
46
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
If
Then
Supplied by BMS (or its vendors):
Records or logs must comply with applicable 
regulations and guidelines and should include:

amount received and placed in storage 
area

amount currently in storage area

label identification number or batch 
number

amount dispensed to and returned by each 
participant, including unique participant 
identifiers

amount transferred to another area/site for 
dispensing or storage

nonstudy disposition (eg, lost, wasted) 

amount destroyed at study site, if 
applicable

amount returned to BMS

retain samples for 
bioavailability/bioequivalence, if 
applicable 

dates and initials of person responsible for 
Investigational Product 
dispensing/accountability, as per the 
Delegation of Authority Form.
Sourced by site, and not supplied by BMS or 
its vendors (examples include IP sourced from 
the sites stock or commercial supply, or a 
specialty pharmacy)
The 
investigator 
or 
designee 
accepts 
responsibility for documenting traceability and 
study treatment integrity in accordance with 
requirements applicable under law and the 
SOPs/standards of the sourcing pharmacy.
BMS or designee will provide forms to facilitate inventory control if the investigational site does 
not have an established system that meets these requirements.
CASE REPORT FORMS
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
Date: 21-Mar-2018
47
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
For sites using the Sponsor or designee electronic data capture tool, electronic CRFs will be 
prepared for all data collection fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electronic SAE form and Pregnancy Surveillance form, respectively. If 
electronic SAE form is not available, a paper SAE form can be used. Spaces may be left blank 
only in those circumstances permitted by study-specific CRF completion guidelines provided by 
Sponsor or designee. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules in accordance with the applicable regulatory requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by the 
investigator or qualified physician who is a subinvestigator and who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not be delegated the CRF approval 
task. For electronic CRFs, review and approval/signature is completed electronically through the 
BMS electronic data capture tool. The investigator must retain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically signing electronic CRFs must meet Sponsor or designee training 
requirements and must only access the BMS electronic data capture tool using the unique user 
account provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individuals.
MONITORING
Sponsor or designee representatives will review data centrally to identify potential issues to 
determine a schedule of on-site visits for targeted review of study records. 
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable. Certain CRF pages and/or electronic files may serve as the source 
documents.
In addition, the study may be evaluated by Sponsor or designee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents, other study files, and study 
facilities. BMS audit reports will be kept confidential.
The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, 
and promptly forward copies of inspection reports to Sponsor or designee. 
RECORDS RETENTION
The investigator (or head of the study site in Japan) must retain all study records and source 
documents for the maximum period required by applicable regulations and guidelines, or 
institution procedures, or for the period specified by BMS or designee, whichever is longer. The 
Date: 21-Mar-2018
48
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associated with the study.
BMS or designee will notify the investigator (or head of the study site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (eg, relocation, retirement), the records shall be 
transferred to a mutually agreed upon designee (eg, another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by BMS, a vendor, or sourced by the investigator) 
such as partially used study treatment containers, vials, and syringes may be destroyed on site. 
If
Then
Study treatments supplied by BMS (including 
its vendors
Any unused study treatments supplied by BMS 
can only be destroyed after being inspected and 
reconciled by the responsible Study Monitor 
unless study treatments containers must be 
immediately destroyed as required for safety, 
or to meet local regulations (eg, cytotoxics or 
biologics).
If study treatments will be returned, the return 
will be arranged by the responsible Study 
Monitor.
Study treatments sourced by site, not supplied 
by BMS (or its vendors) (examples include 
study treatments sourced from the site’s stock 
or 
commercial 
supply, 
or 
a 
specialty 
pharmacy)
It 
is 
the 
investigator’s 
or 
designee’s 
responsibility to dispose of all containers 
according to the institutional guidelines and 
procedures.
It is the investigator’s or designee’s responsibility to arrange for disposal, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met:

On-site disposal practices must not expose humans to risks from the drug.

On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.

Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a copy provided to BMS upon request.

Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. The 
Date: 21-Mar-2018
49
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.

Accountability and disposal records are complete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period.
It is the investigator’s or designee’s responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met, the responsible Study Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors). Destruction of non-study 
treatments sourced by the site, not supplied by BMS, is solely the responsibility of the investigator
or designee.
CLINICAL STUDY REPORT AND PUBLICATIONS
A Signatory Investigator must be selected to sign the clinical study report. 
For this single site protocol, the Principal Investigator for the site will sign the clinical study report.
The data collected during this study are confidential and proprietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTAg) governing [Study site or Investigator] participation in 
the study. These requirements include, but are not limited to, submitting proposed publications to 
Sponsor or designee at the earliest practicable time prior to submission or presentation and 
otherwise within the time period set forth in the CTAg.
Date: 21-Mar-2018
50
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
APPENDIX 3
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW-UP, AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation participant administered study treatment 
and that does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of study treatment, whether or 
not considered related to the study treatment.
Date: 21-Mar-2018
51
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
SERIOUS ADVERSE EVENTS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participant was at risk of death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
Requires inpatient hospitalization or causes prolongation of existing hospitalization (see NOTE 
below)
NOTE: 
The following hospitalizations are not considered SAEs in BMS clinical studies: 

a visit to the emergency room or other hospital department < 24 hours, that does not result 
in admission (unless considered an important medical or life-threatening event)

elective surgery, planned prior to signing consent

admissions as per protocol for a planned medical/surgical procedure

routine health assessment requiring admission for baseline/trending of health status 
(eg, routine colonoscopy)

medical/surgical admission other than to remedy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases

admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical intervention (eg, lack of housing, economic inadequacy, 
caregiver respite, family circumstances, administrative reason)

admission for administration of anticancer therapy in the absence of any other SAEs (applies 
to oncology protocols)
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Is an important medical event (defined as a medical event(s) that may not be immediately 
life-threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the participant or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples 
of such events include, but are not limited to, intensive treatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization.) Potential drug-induced liver injury (DILI) is also considered an important 
medical event. (See Section 9.2.7 for the definition of potential DILI.) 
Date: 21-Mar-2018
52
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the study 
treatment is an SAE. 
Although pregnancy, overdose, cancer, and potential drug-induced liver injury (DILI) are not 
always serious by regulatory definition, these events must be handled as SAEs. (See Section 9.2.5 
for reporting pregnancies).
EVALUATING AES AND SAES
Assessment of Causality
The causal relationship to study treatment is determined by a physician and should be used 
to assess all adverse events (AE). The causal relationship can be one of the following:
Related: There is a reasonable causal relationship between study treatment 
administration and the AE.
Not related: There is not a reasonable causal relationship between study treatment 
administration and the AE. 
The term "reasonable causal relationship" means there is evidence to suggest a causal 
relationship. 
Follow-up of AEs and SAEs
If only limited information is initially available, follow-up reports are required. (Note: 
Follow-up SAE reports must include the same investigator term(s) initially reported.) 
If an ongoing SAE changes in its intensity or relationship to study treatment or if new 
information becomes available, the SAE report must be updated and submitted within 
24 hours to BMS (or designee) using the same procedure used for transmitting the initial 
SAE report.
All SAEs must be followed to resolution or stabilization.
Date: 21-Mar-2018
53
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
REPORTING OF SAES TO SPONSOR OR DESIGNEE

SAEs, whether related or not related to study treatment, and pregnancies must be 
reported to BMS (or designee) within 24 hours of awareness of the event.

SAEs must be recorded on the SAE Report Form; pregnancies must be recorded on a 
Pregnancy Surveillance Form (electronic or paper forms).

The preferred method for SAE data reporting collection is through the eCRF.

The paper SAE/pregnancy surveillance forms are only intended as a back-up option 
when the eCRF system is not functioning.

In this case, the paper forms are to be transmitted via email or confirmed facsimile 
(fax) transmission to:
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
For studies capturing SAEs through electronic data capture (EDC), electronic submission 
is the required method for reporting. In the event the electronic system is unavailable for 
transmission, paper forms must be used and submitted immediately. When paper forms are 
used, the original paper forms are to remain on site.
SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact 
Information list.
Date: 21-Mar-2018
54
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
APPENDIX 4
WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpingectomy, and bilateral oophorectomy.
Women in the following categories are not considered WOCBP

Premenarchal

Premenopausal female with 1 of the following:

Documented hysterectomy

Documented bilateral salpingectomy

Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.

Postmenopausal female

A postmenopausal state is defined as 12 months of amenorrhea in a woman over age 
45 years in the absence of other biological or physiological causes. In addition, females 
under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level 
> 40 mIU/mL to confirm menopause.
Note: Females treated with hormone replacement therapy, (HRT) are likely to have artificially 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the investigators should use their 
judgement in checking serum FSH levels. 

1 week minimum for vaginal hormonal products (rings, creams, gels)

4 week minimum for transdermal products

8 week minimum for oral products
Other parenteral products may require washout periods as long as 6 months. If the serum FSH 
level is > 40 mIU/ml at any time during the washout period, the woman can be considered 
postmenopausal.
CONTRACEPTION GUIDANCE FOR FEMALE PARTICIPANTS OF CHILDBEARING 
POTENTIAL
One of the highly effective methods of contraception listed below is required during study duration 
and until the end of relevant systemic exposure, defined as 5 weeks (33 days) after the end of study 
treatment, plus 30 days.
Date: 21-Mar-2018
55
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
Local laws and regulations may require use of alternative and/or additional contraception methods.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.a

Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulationb 

oral 

intravaginal 

transdermal 

Progestogen-only hormonal contraception associated with inhibition of ovulationb 

oral 

injectable 
Highly Effective Methods That Are User Independent

Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulation b

Intrauterine device (IUD)c

Intrauterine hormone-releasing system (IUS)c

Bilateral tubal occlusion

Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. 

Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
study and the preferred and usual lifestyle of the participant.

It is not necessary to use any other method of contraception when complete abstinence is 
elected. 

WOCBP participants who choose complete abstinence must continue to have pregnancy 
tests, as specified in Section 2. 

Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abstinence 
Date: 21-Mar-2018
56
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
NOTES: 
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical studies. 
b Hormonal contraception may be susceptible to interaction with the study treatment, which may reduce the 
efficacy of the contraceptive method. Hormonal contraception is permissible only when there is sufficient 
evidence that the IMP and other study medications will not alter hormonal exposures such that contraception 
would be ineffective or result in increased exposures that could be potentially hazardous. In this case, alternative 
methods of contraception should be utilized. 
c Intrauterine devices and intrauterine hormone releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exposures from intrauterine devices do not alter 
contraception effectiveness
Less Than Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of >1% per year when used consistently and correctly.

Male or female condom with or without spermicide. Male and female condoms cannot be 
used simultaneously

Diaphragm with spermicide

Cervical cap with spermicide

Vaginal Sponge with spermicide

Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action
Unacceptable Methods of Contraception

Periodic abstinence (calendar, symptothermal, post-ovulation methods)

Withdrawal(coitus interruptus)

Spermicide only

Lactation amenorrhea method (LAM)
CONTRACEPTION GUIDANCE FOR MALE PARTICIPANTS WITH PARTNER(S) OF 
CHILDBEARING POTENTIAL
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to the following during the treatment and until the end of relevant systemic exposure.

Inform any and all partner(s) of their participation in a clinical drug study and the need to 
comply with contraception instructions as directed by the investigator.

Male participants are required to use a condom for study duration and until the end of relevant 
systemic exposure defined as 93 days after the end of treatment in the male participant.

Female partners of males participating in the study to consider use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 93 days after the end of 
treatment in the male participant.

Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile vaginal intercourse or use a male condom during each episode of penile penetration 
during the treatment and until 93 days after the end of treatment. 
Date: 21-Mar-2018
57
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban

Refrain from donating sperm for the duration of the study treatment and for 93 days after the 
end of treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregnancy Information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in Section 9.2.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definitions and procedures for Evaluating, Follow-up and Reporting
Date: 21-Mar-2018
58
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
APPENDIX 5
DIAGNOSTIC CRITERIA FOR DRUG AND ALCOHOL ABUSE
The following is taken from DSM-IV:
Diagnostic Criteria for Psychoactive Substance Dependence
A maladaptive pattern of substance use, leading to clinically significant impairment or distress as 
manifested by 3 (or more) of the following, occurring at any time in the same 12-month period:
1. Tolerance, as defined by either of the following:
a) A need for markedly increased amounts of the substance to achieve intoxication or desired 
effect,
b) Markedly diminished effect with continued use of the same amount of the substance.
2. Withdrawal, as manifested by either of the following:
a) The characteristic withdrawal syndrome for the substance,
b) The same (or closely related) substance is taken to relieve or avoid withdrawal symptoms.
3. The substance is often taken in larger amounts or over a longer period than was intended.
4. There is a persistent desire or unsuccessful efforts to cut down or control substance use.
5. A great deal of time is spent in activities necessary to obtain the substance (eg, visiting multiple 
doctors or driving long distances), use the substance (eg, chain-smoking) or recover from its
effects.
6. Important social, occupational or recreational activities are given up or reduced because of 
substance use.
7. The substance use is continued despite knowledge of having a persistent or recurring physical 
or psychological problem that is likely to have been caused or exacerbated by the substance 
(eg, current cocaine use despite recognition of cocaine-induced depression, or continued 
drinking despite recognition that an ulcer was made worse by alcohol consumption.)
Criteria for Severity of Psychoactive Substance Dependence
Mild: Few, if any, symptoms in excess of those required to make the diagnosis, and the symptoms 
result in no more than mild impairment in occupational functioning or in usual social activities or 
relationships with others.
Moderate: Symptoms or functional impairment between “mild” and “severe”.
Severe: Many symptoms in excess of those required to make the diagnosis, and the symptoms 
markedly interfere with occupational functioning or with usual social activities or relationships 
with others.
In Partial Remission: During the past 6 months, some use of the substance and some symptoms of 
dependence.
In Full Remission: During the past 6 months, either no use of the substance, or use of the substance 
and no symptoms of dependence.
Diagnostic Criteria for Psychoactive Substance Abuse
Date: 21-Mar-2018
59
1.0
Approved
930124947
1.0
v


Clinical Protocol
CV185687
BMS-562247
Apixaban
A. A maladaptive pattern of psychoactive substance use, leading to clinically significant 
impairment or distress as manifested by 1 (or more) of the following, occurring at any time in 
the same 12-month period:
1. Recurrent substance use resulting in a failure to fulfill major role obligations at work, 
school, or home (eg, repeated absences or poor work performance related to substance use; 
substance-related absences, suspensions, or expulsions from school, neglect of children or 
household).
2. Recurrent substance use in situations in which it is physically hazardous (eg, driving an 
automobile or operating a machine when impaired by substance use).
3. Recurrent substance-related legal problems (eg, arrests for substance-related disorderly 
conduct).
4. Continued substance use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of the substance (eg, arguments with spouse 
about consequences of intoxication, physical fights).
B. The symptoms have never met the criteria for substance dependence for this class of substance.
Date: 21-Mar-2018
60
1.0
Approved
930124947
1.0
v



SAP_001.pdf: 












$123(1/$%(/3+$6(5$1'20,=('678'<72(9$/8$7(
7+(%,2$9$,/$%,/,7<2)$3,;$%$1%06PJ
635,1./(&$368/(65(/$7,9(725()(5(1&(PJ7$%/(76
,1+($/7+<3$57,&,3$176

1&71XPEHU1&7
'DWHRI/DVW5HYLVLRQ-XQH 




67$7,67,&$/$1$/<6,63/$1)25
5(/$7,9(%,2$9$,/$%,/,7<2)$3,;$%$1%060*635,1./(
&$368/(6&203$5(':,7+0*7$%/(76,1+($/7+<3$57,&,3$176



9(56,21),1$/
5HYLVLRQ+LVWRU\

5HYLVLRQ
'DWH
5HYLVHG%\
&KDQJHV0DGH5HDVRQVIRUWKH&KDQJH
)LQDO
-XQ


,QLWLDOGUDIWEDVHGRQ2ULJLQDO3URWRFROGDWHG0DU
DQGDGPLQLVWUDWLYHOHWWHUGDWHG$SU








6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ


7$%/(2)&217(176
7$%/(2)&217(176 
 
 
 
678'<'(6&5,37,21 
 
6WXG\'HVLJQ 
 
7UHDWPHQW$VVLJQPHQW 
 
%OLQGLQJDQG8QEOLQGLQJ 
 
3URWRFRO$PHQGPHQWV 
 
2%-(&7,9(6 
 
3ULPDU\ 
 
6HFRQGDU\ 
 
 
 
(1'32,176 
 
(IILFDF\(QGSRLQWV 
 
6DIHW\(QGSRLQWV 
 
3KDUPDFRNLQHWLF(QGSRLQWV 
 
 
 
 
 
6$03/(6,=($1'32:(5 
 
678'<3(5,2'675($70(175(*,0(16$1'3238/$7,216
)25$1$/<6(6 
 
6WXG\3HULRGV 
 
7UHDWPHQW5HJLPHQV 
 
3RSXODWLRQVIRU$QDO\VHV 
 
67$7,67,&$/$1$/<6(6 
 
*HQHUDO0HWKRGV 
 
6WXG\&RQGXFW 
 
6WXG\3RSXODWLRQ 
 
3DUWLFLSDQW'LVSRVLWLRQ 
 
'HPRJUDSKLF&KDUDFWHULVWLFV 
 
3K\VLFDO0HDVXUHPHQWV 
 
0HGLFDO+LVWRU\DQG3UHYLRXV0HGLFDWLRQV 
 
([WHQWRI([SRVXUH 


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ


 
(IILFDF\ 
 
6DIHW\ 
 
'HDWKV 
 
6HULRXV$GYHUVH(YHQWV 
 
$GYHUVH(YHQWV 
 
&OLQLFDO/DERUDWRU\(YDOXDWLRQV 
 
(OHFWURFDUGLRJUDPV 
 
9LWDO6LJQV 
 
3K\VLFDO([DPLQDWLRQ)LQGLQJV 
 
3KDUPDFRNLQHWLFV 
 
([SORUDWRU\3DODWDELOLW\$VVHVVPHQWV 
 
&RQYHQWLRQV 
 
'HFLPDO3ODFHV 
 
3KDUPDFRNLQHWLF6XPPDULHV 
 
&217(172)5(32576 
 
/LVWRI$EEUHYLDWLRQV 
 
 



6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ






















































6FKHGXOHRI$QDO\VHV
)LQDO DQDO\VLV ZLOO EH SHUIRUPHG IROORZLQJ GDWDEDVH ORFN DFFRUGLQJ WR DJUHHGXSRQ UHSRUWLQJ
PLOHVWRQHVW\SLFDOO\DIWHUDOOSDUWLFLSDQWVKDYHFRPSOHWHGWKHVWXG\

678'<'(6&5,37,21

6WXG\'HVLJQ
7KLV LV D 3KDVH  RSHQODEHO UDQGRPL]HG SHULRG WUHDWPHQW FURVVRYHU VWXG\ LQ KHDOWK\
SDUWLFLSDQWV +HDOWK\ PDOH RU IHPDOH SDUWLFLSDQWV DV GHWHUPLQHG E\ PHGLFDO KLVWRU\ SK\VLFDO
H[DPLQDWLRQYLWDOVLJQVOHDGHOHFWURFDUGLRJUDP(&*DQGFOLQLFDOODERUDWRU\WHVWVZLOOEH


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ


HOLJLEOHWRSDUWLFLSDWHLQWKHVWXG\3DUWLFLSDQWVZLOOXQGHUJRVFUHHQLQJHYDOXDWLRQVWRGHWHUPLQH
HOLJLELOLW\ZLWKLQGD\VSULRUWRVWXG\WUHDWPHQWDGPLQLVWUDWLRQ2Q'D\SDUWLFLSDQWVZLOO
HQWHUWKHFOLQLFDOIDFLOLW\DQGEHFRQILQHGIRUWKHGXUDWLRQRIWKHVWXG\XQWLOGLVFKDUJHRQ'D\
3ULRUWRGRVLQJRQ'D\RI3HULRGSDUWLFLSDQWVZLOOEHUDQGRPO\DVVLJQHGWRRIWUHDWPHQW
VHTXHQFHV$%RU%$ZKHUH7UHDWPHQW$LVîPJDSL[DEDQWDEOHWVDQG7UHDWPHQW%LV
îPJDSL[DEDQVSULQNOHFDSVXOHVLQDUDWLR3DUWLFLSDQWVZLOOUHFHLYHDVLQJOHRUDOGRVH
RIDSL[DEDQRQ'D\VDQG7KHUHZLOOEHDGD\ZDVKRXWSHULRGEHWZHHQGRVHV7UHDWPHQWV$
DQG%ZLOOEHSUHSDUHGLQWKHSKDUPDF\
7KHVWXG\GHVLJQVFKHPDWLFLVSUHVHQWHGLQ)LJXUH
)LJXUH
6WXG\'HVLJQ6FKHPDWLF

' 6WXG\'LVFKDUJH ( (QUROOPHQW 5 5DQGRPL]DWLRQ 6 6FUHHQLQJ 7UHDWPHQW$ uPJ DSL[DEDQ
WDEOHWV7UHDWPHQW% uPJDSL[DEDQVSULQNOHFDSVXOHV: :DVKRXW
3K\VLFDO H[DPLQDWLRQV YLWDO VLJQ PHDVXUHPHQWV OHDG (&* DQG FOLQLFDO ODERUDWRU\
HYDOXDWLRQVZLOOEHSHUIRUPHGDWVHOHFWHGWLPHVWKURXJKRXWWKHVWXG\3DUWLFLSDQWVZLOOEHFORVHO\
PRQLWRUHGIRUDGYHUVHHYHQWV$(VWKURXJKRXWWKHVWXG\%ORRGVDPSOHVZLOOEHFROOHFWHGIRUXS
WRKRXUVDIWHUVWXG\GUXJDGPLQLVWUDWLRQIRUSKDUPDFRNLQHWLF3.DQDO\VLV$SSUR[LPDWHO\
P/RIEORRGZLOOEHGUDZQIURPHDFKSDUWLFLSDQWGXULQJWKHVWXG\
3DUWLFLSDQWV ZLOO FRPSOHWH D SDODWDELOLW\ DVVHVVPHQW LPPHGLDWHO\ ZLWKLQ PLQXWHV DIWHU
DGPLQLVWUDWLRQRIWKHDSL[DEDQPJWDEOHWDQGPJVSULQNOHFDSVXOHGRVDJHVRQERWK'D\
DQG'D\

7UHDWPHQW$VVLJQPHQW
(OLJLEOHSDUWLFLSDQWVZLOOEHUDQGRPL]HGLQDUDWLRWRRIWUHDWPHQWVHTXHQFHVDFFRUGLQJWR
DFRPSXWHUJHQHUDWHGUDQGRPL]DWLRQVFKHPHSUHSDUHGE\33'
6WXG\WUHDWPHQWZLOOEHDGPLQLVWHUHGRQ'D\VDQG
(QUROOHGSDUWLFLSDQWVLQFOXGLQJWKRVHQRWGRVHGZLOOEHDVVLJQHGVHTXHQWLDOSDUWLFLSDQWQXPEHUV
VWDUWLQJZLWKHJ7KRVHHQUROOHGSDUWLFLSDQWVPHHWLQJ


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ


LQFOXVLRQDQGH[FOXVLRQFULWHULDZLOOEHHOLJLEOHWREHUDQGRPL]HG5DQGRPL]DWLRQQXPEHUVZLOO
EHDVVLJQHGSULRUWRGRVLQJ
3DUWLFLSDQWV ZLOOQRW EHUHSODFHGLIWKH\ DUHGLVFRQWLQXHGIURP WKHVWXG\VHFRQGDU\WR DQ $(
XQOHVVWKH$(FDQEHGHWHUPLQHGWREHXQUHODWHGWRWUHDWPHQW7KH6SRQVRURUGHVLJQHHPD\
UHSODFH SDUWLFLSDQWV IRU RWKHU UHDVRQV ,I D SDUWLFLSDQW LV UHSODFHG DIWHU GRVLQJ WKHQ WKH
UHSODFHPHQW SDUWLFLSDQW ZLOO EH DVVLJQHG WKH RULJLQDO SDUWLFLSDQW¶V QXPEHU SOXV  7KH
UHSODFHPHQWSDUWLFLSDQWZLOOUHFHLYHWKHVDPHWUHDWPHQWVDVWKHSDUWLFLSDQWEHLQJUHSODFHGEXW
DQHZUDQGRPL]DWLRQQXPEHUZLOOEHDVVLJQHGWRKLPRUKHU)RUH[DPSOH3DUWLFLSDQWZRXOGEH
UHSODFHGE\3DUWLFLSDQW

%OLQGLQJDQG8QEOLQGLQJ
7KLVLVDQRSHQODEHOVWXG\

3URWRFRO$PHQGPHQWV
7KLVVWDWLVWLFDODQDO\VLVSODQ6$3UHIOHFWVWKHDGPLQLVWUDWLYHOHWWHUGDWHG$SULO

2%-(&7,9(6

3ULPDU\
7KHSULPDU\REMHFWLYHIRUWKLVVWXG\LVWRDVVHVVWKHELRDYDLODELOLW\RIDSL[DEDQPJVSULQNOH
FDSVXOHVUHODWLYHWRDSL[DEDQPJWDEOHWVERWKDGPLQLVWHUHGRUDOO\LQKHDOWK\SDUWLFLSDQWV

6HFRQGDU\
7KHVHFRQGDU\REMHFWLYHVIRUWKLVVWXG\DUH
x 7RDVVHVVWKHVDIHW\DQGWROHUDELOLW\RIDSL[DEDQ
x 7RDVVHVVWKH3.RIDSL[DEDQPJVSULQNOHFDSVXOHV
x 7RDVVHVVWKH3.RIDSL[DEDQPJWDEOHWV





(1'32,176

(IILFDF\(QGSRLQWV
7KHUHDUHQRSODQQHGHIILFDF\HQGSRLQWV

6DIHW\(QGSRLQWV
6DIHW\ HQGSRLQWV LQFOXGH LQFLGHQFH RI QRQVHULRXV $(V VHULRXV $(V 6$(V $(V OHDGLQJ WR
GLVFRQWLQXDWLRQRUGHDWKDVZHOODVPDUNHGDEQRUPDOLWLHVLQFOLQLFDOODERUDWRU\WHVWVYLWDOVLJQ
PHDVXUHPHQWVOHDG(&*VDQGSK\VLFDOH[DPLQDWLRQV


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ



3KDUPDFRNLQHWLF(QGSRLQWV
3KDUPDFRNLQHWLF SDUDPHWHUV RI DSL[DEDQ ZLOO EH GHULYHG IURP WKH UHVSHFWLYH SODVPD
FRQFHQWUDWLRQ YHUVXV WLPH GDWD ,QGLYLGXDO 3. SDUDPHWHU YDOXHV ZLOO EH GHULYHG E\
QRQFRPSDUWPHQWDOPHWKRGVE\DYDOLGDWHG3.DQDO\VLVSURJUDPXVLQJDFWXDOWLPHV
7KHSULPDU\3.HQGSRLQWVDUH
x &PD[$8&,1)DQG$8&7RIDSL[DEDQ
7KHVHFRQGDU\3.HQGSRLQWVDUH
x 7PD[7+$/)DQG)UHORIDSL[DEDQ
6SHFLILF3.SDUDPHWHUVDUHVKRZQLQ7DEOH
7DEOH
3KDUPDFRNLQHWLF3DUDPHWHUV1DPLQJ&RQYHQWLRQVDQG'HILQLWLRQV
3DUDPHWHU
'HILQLWLRQ
&PD[
0D[LPXPREVHUYHGSODVPDFRQFHQWUDWLRQ
7PD[
7LPHRIPD[LPXPREVHUYHGSODVPDFRQFHQWUDWLRQ
$8&7
$UHDXQGHUWKHSODVPDFRQFHQWUDWLRQWLPHFXUYHIURPWLPH]HURWRWLPHRIODVW
TXDQWLILDEOHFRQFHQWUDWLRQ
$8&,1)
$UHDXQGHUWKHSODVPDFRQFHQWUDWLRQWLPHFXUYHIURPWLPH]HURH[WUDSRODWHGWRLQILQLWH
WLPH
7+$/)
7HUPLQDOSODVPDKDOIOLIH
)UHO
5HODWLYHELRDYDLODELOLW\








6$03/(6,=($1'32:(5
7KHVLPLODULW\RIWKHELRDYDLODELOLW\ZLOOEHFRQFOXGHGLIWKHFRQILGHQFHLQWHUYDO&,IRUWKH
UDWLR RI JHRPHWULF PHDQV RI DSL[DEDQ PJ VSULQNOH FDSVXOHV UHODWLYH WR DSL[DEDQ PJ
WDEOHWVDUHZKROO\FRQWDLQHGZLWKLQDQGIRU&PD[DQG$8& 7KHIROORZLQJWDEOH
VKRZV WKH SRZHU SURYLGHG ZLWK GDWD IURP  3. HYDOXDEOH SDUWLFLSDQWV EDVHG RQ GLIIHUHQW
DVVXPSWLRQVRIGLIIHUHQFHEHWZHHQWKHELRDYDLODELOLW\RIDSL[DEDQPJVSULQNOHFDSVXOHVDQG
DSL[DEDQPJWDEOHWV


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ


7UXH*HRPHWULF
0HDQ5DWLR
3RZHURI&PD[
3RZHURI
$8&7
3RZHURI
$8&,1)
2YHUDOO3RZHU






























$V DQ H[DPSOH LI WKHUH LV D  GLIIHUHQFH EHWZHHQ WKH ELRDYDLODELOLW\ RI DSL[DEDQ PJ
VSULQNOHFDSVXOHVDQGDSL[DEDQPJWDEOHWVWKHQGDWDIURP3.HYDOXDEOHSDUWLFLSDQWVZLOO
SURYLGHDSSUR[LPDWHO\DQGSRZHUWRFRQFOXGHVLPLODUELRDYDLODELOLW\IRU&PD[
$8&,1)DQG$8&7UHVSHFWLYHO\7KHRYHUDOOSRZHUIRUWKLVK\SRWKHVLVLVDSSUR[LPDWHO\

7KHVHFDOFXODWLRQVXVHWKHDSSURDFKGHVFULEHGE\'LOHWWLHWDODQGDVVXPH&PD[DQG$8&DUH
ORJQRUPDOO\GLVWULEXWHGZLWKLQWUDVXEMHFWFRHIILFLHQWRIYDULDWLRQ&9RIIRU&PD[DQG
IRU$8&DVHVWLPDWHGIURPDSL[DEDQ6WXG\&9DQG6WXG\&97RDOORZ
IRUSRVVLEOHGURSRXWVDWRWDORISDUWLFLSDQWVDUHSODQQHGWREHUDQGRPL]HGWRREWDLQDWOHDVW
3.HYDOXDEOHSDUWLFLSDQWV

678'<3(5,2'675($70(175(*,0(16$1'3238/$7,216)25
$1$/<6(6

6WXG\3HULRGV
x 7KHSUHWUHDWPHQWSHULRGZLOOEHIURPWKHWLPHWKH,QIRUPHG&RQVHQW)RUP,&)LVVLJQHG
XQWLO WKH WLPH MXVW SULRU WR GRVLQJ RQ 'D\  IRU DOO SDUWLFLSDQWV 7KH SUHWUHDWPHQW SHULRG
VKRXOG EH QR ORQJHU WKDQ  GD\V DQG ZLOO LQFOXGH DOO VFUHHQLQJ HQUROOPHQW 'D\ 
UDQGRPL]DWLRQDQG'D\SUHGRVHSURFHGXUHV
x 3HULRGZLOOEHIURPWKHWLPHRIGRVLQJRQ'D\XQWLOWKHWLPHSULRUWRGRVLQJLQWKHQH[W
SHULRGRQ'D\RUXQWLOVWXG\GLVFKDUJHGXHWRSUHPDWXUHGLVFRQWLQXDWLRQLIWKHSDUWLFLSDQW
LVQRWGRVHGRQ'D\
x 3HULRGZLOOEHIURPWKHWLPHRIGRVLQJRQ'D\XQWLOWKHSDUWLFLSDQWLVGLVFKDUJHGRQ'D\
RUXQWLOWKHGD\RIVWXG\GLVFKDUJHGXHWRSUHPDWXUHGLVFRQWLQXDWLRQDIWHUGRVLQJRQ'D\
x ,IDSDUWLFLSDQWLVQRWGLVFKDUJHGRQ'D\DQ\GDWDFROOHFWHGDIWHU'D\ZLOOEHDVVLJQHGWR
WKHSRVWWUHDWPHQWSHULRG
x 3HULRGVDQGZLOOEHFRQVLGHUHGRQWKHUDS\IRUWKHSXUSRVHRIVDIHW\DQDO\VHV
7KHGHILQLWLRQRIHDFKVWXG\SHULRGLVLQFOXGHGLQ7DEOH


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ


7DEOH
'HILQLWLRQRI6WXG\3HULRG
3(5,2'
6(48(1&(
3(5,2'
1$0(
'$7(72%(86('
'(),1,7,21

35(
75($70(17
&216(17'$7(
'26('$7(7,0(21'$<
6WDUWLQJZLWKFRQVHQWGDWHDQGHQGLQJE\
GRVHGDWHDQGWLPHRQ'D\

3(5,2'
'26('$7(7,0(21'$<
'26('$7(7,0(21'$<
6WDUWLQJZLWKGRVHGDWHDQGWLPHRQ'D\
DQGHQGLQJE\GRVHGDWHDQGWLPH
RQ'D\

3(5,2'
'26('$7(7,0(21'$<
',6&+$5*('$7(
6WDUWLQJZLWKGRVHGDWHDQGWLPHRQ'D\
DQGHQGLQJE\GLVFKDUJHGDWH

3267
75($70(17
',6&+$5*('$7(
6WDUWLQJZLWKGLVFKDUJHGDWH


7UHDWPHQW5HJLPHQV
7KHIROORZLQJWUHDWPHQWVZLOOEHDGPLQLVWHUHGLQWKLVVWXG\ZLWKDUDWLRLQVHTXHQFHVRI$%
DQG%$
x 7UHDWPHQW$ îPJDSL[DEDQWDEOHWV
x 7UHDWPHQW% îPJDSL[DEDQVSULQNOHFDSVXOHV

3RSXODWLRQVIRU$QDO\VHV
x (QUROOHG3RSXODWLRQGHILQHGDVDOOSDUWLFLSDQWVZKRVLJQHGWKH,&)
x 5DQGRPL]HG 3RSXODWLRQ GHILQHG DV DOO SDUWLFLSDQWV ZKR DUH UDQGRPL]HG WR D VHTXHQFH RI
WUHDWPHQWV
x 7UHDWHG 3RSXODWLRQ GHILQHG DV DOO SDUWLFLSDQWV ZKR UHFHLYHG DW OHDVW  GRVH RI VWXG\
WUHDWPHQW
x 3KDUPDFRNLQHWLF3RSXODWLRQGHILQHGDVDOOSDUWLFLSDQWVZKRUHFHLYHGDWOHDVWGRVHRIVWXG\
WUHDWPHQW DQGKDGDQ\ DYDLODEOHFRQFHQWUDWLRQWLPHGDWD3KDUPDFRNLQHWLFOLVWLQJV DQG3.
SDUDPHWHUFDOFXODWLRQVZLOOEHEDVHGRQWKLVSRSXODWLRQ
x (YDOXDEOH3.3RSXODWLRQLVDVXEVHWRIWKH3KDUPDFRNLQHWLFSRSXODWLRQ7KH(YDOXDEOH3.
SRSXODWLRQLQFOXGHVDOOSDUWLFLSDQWVZKRKDGDGHTXDWH3.SURILOHVIRUDFFXUDWHHVWLPDWLRQRI
3.SDUDPHWHUVDQGKDGQRSURWRFROGHYLDWLRQVFRQVLGHUHGWRDIIHFWWKH3.DVVHVVPHQWV
$OODYDLODEOHGHULYHG3.SDUDPHWHUYDOXHVZLOOEHLQFOXGHGLQWKH3.GDWDVHWDQGUHSRUWHGEXW
RQO\SDUWLFLSDQWVZLWKHYDOXDEOH3.GDWDZLOOEHLQFOXGHGLQWKHVXPPDU\VWDWLVWLFVDQGVWDWLVWLFDO
DQDO\VLV

67$7,67,&$/$1$/<6(6
6$6 YHUVLRQ  RU KLJKHU ZLOO EH XVHG IRU VWDWLVWLFDO DQDO\VHV WDEXODWLRQV DQG JUDSKLFDO
SUHVHQWDWLRQV


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ



*HQHUDO0HWKRGV
$OO GDWD UHFRUGHG RQ FDVH UHSRUW IRUPV &5)V ZLOO EH OLVWHG E\ SDUWLFLSDQW 'HVFULSWLYH
VXPPDULHVZLOOEHSUHVHQWHGIRUFRQWLQXRXVYDULDEOHVXVLQJQXPEHURISDUWLFLSDQWV1PHDQ
VWDQGDUGGHYLDWLRQ6'PHGLDQPLQLPXPDQGPD[LPXP*HRPHWULFPHDQDQG&9ZLOODOVR
EHSUHVHQWHGIRUVDPSOHSODVPD3.SDUDPHWHUV'HVFULSWLYHVXPPDULHVIRUFDWHJRULFDOYDULDEOHV
ZLOOXWLOL]HFRXQWVDQGSHUFHQWDJHV
:KHUHDSSURSULDWHEDVHOLQHLVGHILQHGDVWKHODVWQRQPLVVLQJUHVXOWZLWKDFROOHFWLRQGDWHWLPH
OHVVWKDQWKHGDWHWLPHRIWKHILUVWGRVHRIVWXG\WUHDWPHQW
$GYHUVH HYHQWV DQG PHGLFDO KLVWRU\ ZLOO EH FRGHG DFFRUGLQJ WR WKH PRVW UHFHQW 0HGLFDO
'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV0HG'5$YHUVLRQ3UHYLRXVDQGFRQFRPLWDQWPHGLFDWLRQV
ZLOO EH FRGHG XVLQJ WKH :RUOG +HDOWK 2UJDQL]DWLRQ :+2 'UXJ 'LFWLRQDU\ YHUVLRQ WR EH
GHOLQHDWHGLQWKHFOLQLFDOVWXG\UHSRUW&65

6WXG\&RQGXFW
'HYLDWLRQVIURPWKHVWXG\SURWRFROSURWRFRODPHQGPHQWVDQGDGPLQLVWUDWLYHFKDQJHVZLOOEH
GRFXPHQWHG 1R SRWHQWLDO SURWRFRO GHYLDWLRQV DUH GHILQHG DV EHLQJ UHOHYDQW LQ WKLV KHDOWK\
YROXQWHHUVWXG\OLVWLQJRIUHOHYDQWSURWRFROGHYLDWLRQVZLOOQRWEHSURYLGHG

6WXG\3RSXODWLRQ
 3DUWLFLSDQW'LVSRVLWLRQ
3DUWLFLSDQWGLVSRVLWLRQZLOOEHOLVWHG6XPPDU\WDEOHVUHIOHFWLQJWKHQXPEHURISDUWLFLSDQWVZKR
DUH HQUROOHG ZKR DUH UDQGRPL]HG ZKR DUH QRW UDQGRPL]HG DQG UHDVRQV IRU QRW EHLQJ
UDQGRPL]HGZLOOEHSUHVHQWHGDVRYHUDOOIRUWKHHQUROOHGSRSXODWLRQ
7KHQXPEHURISDUWLFLSDQWVZKRFRPSOHWHWKHVWXG\ZKRGRQRWFRPSOHWHWKHVWXG\DQGUHDVRQV
IRUQRWFRPSOHWLQJWKHVWXG\ZLOOEHVXPPDUL]HGIRUWKHWUHDWHGSRSXODWLRQDVRYHUDOODQGE\
WUHDWPHQWVHTXHQFH
 'HPRJUDSKLF&KDUDFWHULVWLFV
'HPRJUDSKLFFKDUDFWHULVWLFVVXFKDVJHQGHUDJHUDFHDQGHWKQLFLW\ZLOOEHOLVWHGIRUWKHWUHDWHG
SRSXODWLRQ'HPRJUDSKLFFKDUDFWHULVWLFVZLOODOVREHVXPPDUL]HGIRUWKHWUHDWHGSRSXODWLRQDV
RYHUDOODQGE\WUHDWPHQWVHTXHQFH
 3K\VLFDO0HDVXUHPHQWV
3K\VLFDOPHDVXUHPHQWVVXFKDVERG\ZHLJKWKHLJKWDQGERG\PDVVLQGH[%0,ZLOOEHOLVWHG
IRU WKH WUHDWHG SRSXODWLRQ 0HDVXUHPHQWV ZLOO DOVR EH VXPPDUL]HG E\ QRPLQDO YLVLW IRU WKH
WUHDWHGSRSXODWLRQDVRYHUDOODQGE\WUHDWPHQWVHTXHQFH
 0HGLFDO+LVWRU\DQG3UHYLRXV0HGLFDWLRQV
0HGLFDO KLVWRU\ DQG SUHYLRXV PHGLFDWLRQV WDNHQ SULRU WR GRVLQJ ZLOO EH OLVWHG IRU WKH WUHDWHG
SRSXODWLRQ


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ



([WHQWRI([SRVXUH
1RDQDO\VLVUHJDUGLQJH[WHQWRIH[SRVXUHLVSODQQHG5DQGRPL]DWLRQVFKHGXOHZLOOEHOLVWHGIRU
WKHUDQGRPL]HGSRSXODWLRQ6WXG\GUXJDGPLQLVWUDWLRQDQGEDWFKQXPEHUVZLOOEHOLVWHGIRUWKH
WUHDWHG SRSXODWLRQ $Q\ QRQVWXG\ PHGLFDWLRQV WDNHQ E\ SDUWLFLSDQWV DQ\ QRQVWXG\ PHGLFDO
WUHDWPHQWSURFHGXUHVFRQGXFWHGDQGDQ\QRQVWXG\GLDJQRVWLFSURFHGXUHVXWLOL]HGZLOODOVREH
OLVWHGIRUWKHWUHDWHGSRSXODWLRQ

(IILFDF\
7KHUHDUHQRHIILFDF\DVVHVVPHQWVLQWKHVWXG\

6DIHW\
$QDO\VLV RI DOO VDIHW\ GDWD ZLOO IROORZ WKH %06 JXLGHOLQH RI DQDO\VLV RI VDIHW\ GDWD 7KH
HYDOXDWLRQRIVDIHW\LVEDVHGRQFOLQLFDO$(VYLWDOVLJQV(&*UHVXOWVFOLQLFDOODERUDWRU\UHVXOWV
DQGDEQRUPDOSK\VLFDOH[DPLQDWLRQVUHSRUWHGGXULQJWKHVWXG\
8QOHVV RWKHUZLVH VSHFLILHG DOO VDIHW\ SUHVHQWDWLRQV ZLOO XWLOL]H WKH WUHDWHG SRSXODWLRQ DV
GHVFULEHGLQ6HFWLRQ
$OOGDWDFROOHFWHGIURPWKHVDPSOLQJRXWVLGHWKHVFKHGXOHGYLVLWVZLOORQO\EHLQFOXGHGLQWKH
OLVWLQJDQGZLOOEHH[FOXGHGIURPWKHVXPPDU\WDEOHV
 'HDWKV
$OOGHDWKVUHSRUWHGDIWHUDSDUWLFLSDQWLVHQUROOHGLHKDVVLJQHGWKH,&)ZLOOEHOLVWHGIRUWKH
HQUROOHGSRSXODWLRQ
 6HULRXV$GYHUVH(YHQWV
$OOUHSRUWHG6$(VZLOOEHOLVWHGIRUWKHHQUROOHGSRSXODWLRQ
 $GYHUVH(YHQWV
$GYHUVHHYHQWVWKDWRFFXURQRUDIWHUWKHILUVWGRVHRIVWXG\WUHDWPHQWZLOOEHWDEXODWHG(YHQWV
ZLOOEHDVVLJQHGWRWKHODVWVWXG\WUHDWPHQWDGPLQLVWHUHGDWWKHWLPHRIRQVHW1RQVHULRXV$(V
RFFXUULQJIRUXSWRGD\VDIWHUWKHWHUPLQDWLRQRIVWXG\WUHDWPHQWDQG6$(VRFFXUULQJIRUXSWR
 GD\V DIWHU WKH WHUPLQDWLRQ RI VWXG\ WUHDWPHQW ZLOO EH LQFOXGHG LQ VXPPDU\ VWDWLVWLFV 7KH
SURSRUWLRQRISDUWLFLSDQWVKDYLQJDQ$(ZLOOEHFDOFXODWHGDVWKHQXPEHURISDUWLFLSDQWVKDYLQJ
WKHHYHQWLQWKHVSHFLILFWUHDWPHQWLQWHUYDOGLYLGHGE\WKHWRWDOQXPEHURISDUWLFLSDQWVUHFHLYLQJ
VWXG\WUHDWPHQWGXULQJWKDWWUHDWPHQWLQWHUYDO
$OO$(OLVWLQJVZLOOLQGLFDWHWKHXQLTXHSDUWLFLSDQWLGHQWLILHUDJHJHQGHUFXUUHQWWUHDWPHQWWKH
GDWHRIRQVHWWKHGDWHRIUHVROXWLRQGD\RIRQVHWUHODWLYHWRWKHVWDUWRIWUHDWPHQWDFWLRQWDNHQ
LQYHVWLJDWRU¶VDVVHVVPHQWRIVHYHULW\DQGUHODWLRQVKLSWRVWXG\GUXJ$GGLWLRQDOOLVWLQJVZLOOEH
SURYLGHGIRU$(VOHDGLQJWRGLVFRQWLQXDWLRQDQG$(VZLWKRXWUHFRUGHGUHVROXWLRQ
$OO$(VZLOOEHVXPPDUL]HGE\V\VWHPRUJDQFODVV62&SUHIHUUHGWHUP37WUHDWPHQWDQG
WRWDOIRUWKHWUHDWHGSRSXODWLRQ6XPPDULHVRI$(VZLOOLQFOXGH$(V$(VE\LQWHQVLW\DQG$(V
UHODWHGWRVWXG\GUXJ


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ


$GYHUVH(YHQW&RXQWLQJ5XOHV
:KHUHDSDUWLFLSDQWKDVWKHVDPH$(EDVHGRQ37UHSRUWHGPXOWLSOHWLPHVLQDVLQJOHDQDO\VLV
SHULRGWKHSDUWLFLSDQWZLOORQO\EHFRXQWHGRQFHDWWKH37OHYHOLQ$(IUHTXHQF\WDEOHV
:KHUH D SDUWLFLSDQW KDV PXOWLSOH $(V ZLWKLQ WKH VDPH 62& LQ D VLQJOH DQDO\VLV SHULRG WKH
SDUWLFLSDQWZLOORQO\EHFRXQWHGRQFHDWWKH62&OHYHOLQ$(IUHTXHQF\WDEOHV
:KHQDSDUWLFLSDQWKDVWKHVDPH$(EDVHGRQ37UHSRUWHGPXOWLSOHWLPHVLQDVLQJOHDQDO\VLV
SHULRG WKH IROORZLQJ FULWHULD LQ RUGHU RI SUHFHGHQFH ZLOO EH XVHG WR VHOHFW WKH HYHQW WR EH
LQFOXGHGLQVXPPDU\WDEOHV
x 5HODWLRQVKLSWRVWXG\GUXJ
x ,QWHQVLW\RIHYHQW
x 2QVHWGDWHDQGWLPH
:KHQUHSRUWLQJ$(VE\LQWHQVLW\LQDGGLWLRQWRSURYLGLQJDVXPPDU\WDEOHEDVHGRQWKHHYHQW
VHOHFWLRQFULWHULDGHWDLOHGDERYHVXPPDU\WDEOHVZLOODOVREHSURYLGHGEDVHGRQWKHPRVWLQWHQVH
HYHQW GXULQJ WKH DQDO\VLV SHULRG LQGHSHQGHQW RI UHODWLRQVKLS WR VWXG\ PHGLFDWLRQ )RU WKHVH
WDEOHV WKH IROORZLQJ FULWHULD LQ RUGHU RI SUHFHGHQFH ZLOO EH XVHG WR VHOHFW WKH HYHQW WR EH
LQFOXGHGLQVXPPDU\WDEOHV
x ,QWHQVLW\RIHYHQW
x 2QVHWGDWHDQGWLPH
3DUWLFLSDQWVZLOORQO\EHFRXQWHGRQFHLQWKHµ7RWDO¶DWWKHLUPD[LPXPLQWHQVLW\UHJDUGOHVVRI
62&RU37
 &OLQLFDO/DERUDWRU\(YDOXDWLRQV
7KHUHVXOWVRIDOOSURWRFROVSHFLILHGFOLQLFDOODERUDWRU\WHVWVZLOOEHOLVWHGE\SDUWLFLSDQWIRUWKH
WUHDWHGSRSXODWLRQ
/DERUDWRU\HYDOXDWLRQVZLOOEHUHSRUWHGERWKLQFRQYHQWLRQDOXQLWVDQGLQ,QWHUQDWLRQDO6\VWHPRI
8QLWV
/DERUDWRU\ UHVXOWV ZLOOEHFODVVLILHG DVPDUNHGO\ DEQRUPDO EDVHGRQVSRQVRUGHILQHG FULWHULD
/DERUDWRU\ UHVXOWV IRU SDUWLFLSDQWV ZLWK DQ\ PDUNHG ODERUDWRU\ DEQRUPDOLW\ VFKHGXOHG DQG
XQVFKHGXOHGZLOOEHOLVWHGIRUWKHWUHDWHGSRSXODWLRQ7KLVOLVWLQJZLOOLQFOXGHDOOREVHUYDWLRQV
IRU WKH VSHFLILF ODERUDWRU\ WHVW DQG SDUWLFLSDQW QRW RQO\ WKH PDUNHG ODERUDWRU\ DEQRUPDOLW\
PHDVXUHPHQWV 7KH IUHTXHQF\ RI SDUWLFLSDQWV ZLWK DQ\ RQWUHDWPHQW PDUNHG ODERUDWRU\
DEQRUPDOLW\ EDVHG RQ SUHVSHFLILHG FULWHULD ZLOO EH SUHVHQWHG IRU WKH WUHDWHG SRSXODWLRQ E\
WUHDWPHQWDQGWRWDO
 (OHFWURFDUGLRJUDPV
$OOUHFRUGHG(&*VZLOOEHOLVWHGIRUWKHWUHDWHGSRSXODWLRQ
,I47LQWHUYDOFRUUHFWHGIRUKHDUWUDWHXVLQJ)ULGHULFLD¶VIRUPXOD47F)LVQRWDYDLODEOHLQWKH
GDWDEDVH47F)ZLOOEHFDOFXODWHGXVLQJWKHUHSRUWHGXQFRUUHFWHG47,QWHUYDODQGKHDUWUDWHDQG
WKHIROORZLQJIRUPXOD


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ








5$7(
+($57
47
47F)  

3DUWLFLSDQWVZLWK(&*LQWHUYDOVRXWVLGHRIDSUHVSHFLILHGUDQJHDQGLQYHVWLJDWRULGHQWLILHG(&*
DEQRUPDOLWLHVZLOODOVREHOLVWHGIRUWKHWUHDWHGSRSXODWLRQ
7KHIROORZLQJFULWHULDZLOOEHXVHGWRGHWHUPLQH(&*UHVXOWVWKDWDUHRXWVLGHRIDSUHVSHFLILHG
UDQJH
35PVHF
9DOXH!
456PVHF
9DOXH!
47PVHF
9DOXH!RUFKDQJHIURPEDVHOLQH!
47F)PVHF
9DOXH!RUFKDQJHIURPEDVHOLQH!

 9LWDO6LJQV
9LWDOVLJQVSDUDPHWHUVV\VWROLFEORRGSUHVVXUH>%3@GLDVWROLF%3KHDUWUDWHUHVSLUDWRU\UDWHDQG
ERG\WHPSHUDWXUHZLOOEHOLVWHGIRUWKHWUHDWHGSRSXODWLRQ
3DUWLFLSDQWVZLWKYLWDOVLJQVRXWVLGHRIDSUHVSHFLILHGUDQJHZLOODOVREHOLVWHGIRUWKHWUHDWHG
SRSXODWLRQ
7KH IROORZLQJ FULWHULD ZLOO EH XVHG WR GHWHUPLQH YLWDO VLJQ UHVXOWV WKDW DUH RXWVLGH RI
DSUHVSHFLILHGUDQJHZKHUHFKDQJHVIURPEDVHOLQHDUHEDVHGRQPDWFKHGSRVWXUDOSRVLWLRQVDQG
DUHFDOFXODWHGDVSDUDPHWHUYDOXHEDVHOLQHSDUDPHWHUYDOXH
+HDUW5DWHESP
9DOXH!DQGFKDQJHIURPEDVHOLQH!RU
9DOXHDQGFKDQJHIURPEDVHOLQH
6\VWROLF%3PP+J
9DOXH!DQGFKDQJHIURPEDVHOLQH!RU
9DOXHDQGFKDQJHIURPEDVHOLQH
'LDVWROLF%3PP+J
9DOXH!DQGFKDQJHIURPEDVHOLQH!RU
9DOXHDQGFKDQJHIURPEDVHOLQH
5HVSLUDWLRQEUHDWKVPLQ
9DOXH!RUFKDQJHIURPEDVHOLQH!
7HPSHUDWXUH&
9DOXH!&RUFKDQJHIURPEDVHOLQH!&

 3K\VLFDO([DPLQDWLRQ)LQGLQJV
$OOSK\VLFDOH[DPLQDWLRQDEQRUPDOILQGLQJVZLOOEHOLVWHGSHUSDUWLFLSDQWDQGYLVLWIRUWKHWUHDWHG
SRSXODWLRQ

3KDUPDFRNLQHWLFV
7KH3.SRSXODWLRQZLOOEHXVHGIRUDOO3.OLVWLQJV7KH(YDOXDEOH3.SRSXODWLRQZLOOEHXVHGIRU
VXPPDU\ VWDWLVWLFV DQG VWDWLVWLFDO DQDO\VHV $QDO\VLV ZLOO LQFOXGH DOO YDOLG DQDO\WH GDWD IRU
DSL[DEDQ


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ


3DUWLFLSDQWSODVPDFRQFHQWUDWLRQWLPHSURILOHVZLOOEHOLVWHGDQGVXPPDUL]HGE\WUHDWPHQWDQG
QRPLQDOFROOHFWLRQWLPHIRUDSL[DEDQ3ORWVRILQGLYLGXDOSODVPDFRQFHQWUDWLRQSURILOHVRYHUWLPH
ZLOOEHSURYLGHG2YHUOD\VRILQGLYLGXDOSODVPDFRQFHQWUDWLRQSURILOHVRYHUWLPHZLOOEHSURYLGHG
E\WUHDWPHQW3ORWVRIPHDQ6'SODVPDFRQFHQWUDWLRQSURILOHVYHUVXVWLPHZLOOEHSUHVHQWHG
IRUDSL[DEDQDQGDOOWUHDWPHQWVZLOOEHVXSHULPSRVHGRQWKHVDPHSORW
$OOLQGLYLGXDO3.SDUDPHWHUVZLOOEHOLVWHGIRUDSL[DEDQLQFOXGLQJDQ\H[FOXVLRQVDQGUHDVRQVIRU
H[FOXVLRQ6XPPDU\VWDWLVWLFVZLOOEHWDEXODWHGIRUHDFK3.SDUDPHWHUE\WUHDWPHQW*HRPHWULF
PHDQV DQG &9 ZLOO EH SUHVHQWHG IRU &PD[ $8&7 $8&,1) DQG )UHO 0HGLDQV DQG
UDQJHVZLOOEHSUHVHQWHGIRU7PD[0HDQVDQG6'VZLOOEHSUHVHQWHGIRURWKHU3.SDUDPHWHUVLH
7+$/)'HFLPDOSODFHVSHFLILFDWLRQVIRUVXPPDU\VWDWLVWLFVDUHGHVFULEHGLQ6HFWLRQ
$ OLQHDU PL[HG HIIHFW PRGHO ZLWK WUHDWPHQW DQG SHULRG DV IL[HG HIIHFWV DQG SDUWLFLSDQW DV
UHSHDWHGPHDVXUHVZLOOEHILWWHGWRWKHORJWUDQVIRUPHG3.SDUDPHWHUV&PD[$8&>7@DQG
$8&>,1)@IRUXVHLQHVWLPDWLRQRIHIIHFWVDQGFRQVWUXFWLRQRI&,V.HQZDUG5RJHUVGHJUHHVRI
IUHHGRP ZLOO EH VSHFLILHG LQ WKH PRGHO ,QLWLDO HVWLPDWLRQ RI WKH YDULDQFHFRYDULDQFH ZLOO EH
EDVHG RQ DQ XQVWUXFWXUHG 81 5 PDWUL[ DVVXPLQJ QR FRPPRQ YDULDQFHV RU FRYDULDQFHV
KRZHYHUWKLV81PDWUL[ZLOOEHDVVHVVHGDQGWKHPRUHSDUVLPRQLRXVFRPSRXQGV\PPHWU\&6
5PDWUL[ZLOOEHLPSRVHGLIDVVXPSWLRQVRIFRPPRQYDULDQFHVDQGFRYDULDQFHVDUHUHDVRQDEOH
DQGFDQEHVXSSRUWHGE\WKHGDWD3RLQWHVWLPDWHVDQG&,VZLOOEHH[SRQHQWLDWHGDQGUHVXOWV
ZLOOEHUHSRUWHGRQWKHRULJLQDOVFDOH
6SHFLILFGHWDLOV ZLWK DSSURSULDWH6$6 FRGHDUH SURYLGHGEHORZ $SL[DEDQDV PJVSULQNOH
FDSVXOHV7UHDWPHQW%LVWKHWHVWWUHDWPHQWDQGDSL[DEDQDVPJWDEOHWV7UHDWPHQW$LVWKH
UHIHUHQFHWUHDWPHQWLQWKHDQDO\VLV
352&0,;(''$7$ 3.'$7$
%<>ORJWUDQVIRUPHG3.SDUDPHWHUVXFKDV&PD[$8&,1)$8&7@
&/$6675($70(173(5,2'868%-,'
02'(//2*B3. 3(5,2'75($70(1762/87,21'')0 .5
5(3($7('75($70(1768%-(&7 868%-,'7<3( 815
/60($1675($70(17&/$/3+$ 
(67,0$7(µ%YV$¶75($70(17(&/$/3+$ 
58148,7

3ORWV RI LQGLYLGXDO WUHDWPHQW UDWLRV RI 3. SDUDPHWHUV &PD[ $8&>,1)@ DQG $8&>7@
FRPELQHGZLWKJHRPHWULFOHDVWVTXDUHPHDQUDWLRV*05VDQGFRUUHVSRQGLQJ&,VIURPWKH
VWDWLVWLFDODQDO\VLVPRGHOZLOODOVREHSURYLGHG,QDGGLWLRQWKH*05VDQGFRUUHVSRQGLQJ
&,VIRU$8&7$8&,1)DQG&PD[IRUDSL[DEDQZLOOEHVXPPDUL]HGLQIRUHVWSORWVIRU
RYHUDOO DVVHVVPHQW RI WKH UHODWLYH ELRDYDLODELOLW\ RI WKH WHVW WUHDWPHQW VSULQNOH FDSVXOHV
FRPSDUHGWRWKHUHIHUHQFHWUHDWPHQWWDEOHWV






6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ



&RQYHQWLRQV
(P%$5& (QKDQFHG %LRPHWULF $QDO\VLV 	 5HSRUWLQJ &DSDELOLW\ VWDQGDUG WLPH ZLQGRZLQJ
LPSXWDWLRQUXOHVDQGFRXQWLQJUXOHVZLOOEHDSSOLHG
 'HFLPDO3ODFHV
7KH QXPEHU RI GHFLPDO SODFHV GLVSOD\HG LQ DOO OLVWLQJV ZLOO EH GHWHUPLQHG E\ WKH QXPEHU RI
GHFLPDOSODFHVLQWKHUDZGDWD
8QOHVVRWKHUZLVHVSHFLILHGPLQLPXPDQGPD[LPXPZLOOEHUHSRUWHGWRWKHVDPHSUHFLVLRQDVWKH
GDWDFROOHFWHGPRUHGHFLPDOSODFHIRUWKHPHDQPHGLDQDQG6'DQGPRUHGHFLPDOSODFHV
IRUWKHVWDQGDUGHUURU6(7KH*05DQGWKHORZHUDQGXSSHUOLPLWVRI&,ZLOOEHGLVSOD\HGWR
GHFLPDOSODFHV
)RUSHUFHQWFKDQJHIURPEDVHOLQHGDWDPLQLPXPDQGPD[LPXPZLOOEHUHSRUWHGZLWKGHFLPDO
SODFHVPHDQPHGLDQDQG6'ZLOOEHUHSRUWHGZLWKGHFLPDOSODFHDQG6(ZLOOEHUHSRUWHG
ZLWKGHFLPDOSODFHV
7KHLQFLGHQFHUDWHZLOOEHURXQGHGWRGHFLPDOSODFH,IWKHLQFLGHQFHUDWHLVOHVVWKDQ
WKHQ³´ZLOOEHGLVSOD\HG
7KUHHGHFLPDOSODFHVIRUUDWLRVZLOOEHXVHGIRUGDWDSUHVHQWDWLRQ
 3KDUPDFRNLQHWLF6XPPDULHV
,QWH[W7DEOHV
)RU LQWH[W 3. WDEOHV &9 ZLOO EH UHSRUWHG DV LQWHJHUV )RU RWKHU VWDWLVWLFV H[FHSW IRU 6'V
YDOXHVRIRUKLJKHUZLOOEHSUHVHQWHGDVLQWHJHUVYDOXHVRIZLOOEHGLVSOD\HGWR
GHFLPDOSODFHDQGYDOXHVRIZLOOEHGLVSOD\HGWRGHFLPDOSODFHV9DOXHVOHVVWKDQ
ZLOOEHGLVSOD\HGWRGHFLPDOSODFHV5DWLRVZLOODOVREHGLVSOD\HGWRGHFLPDOSODFHV6WDQGDUG
GHYLDWLRQVZLOOEHUHSRUWHGWRDSUHFLVLRQRIGHFLPDOSODFHPRUHWKDQWKHPHDQ
+DQGOLQJRI1RQ4XDQWLILDEOH&RQFHQWUDWLRQV
)RUWKHVXPPDULHVRISODVPDFRQFHQWUDWLRQWLPHGDWDFRQFHQWUDWLRQVWKDWDUHOHVVWKDQWKHORZHU
OLPLWRITXDQWLILFDWLRQ//24VKRXOGEHGLVSOD\HGDV³//24´LQWKHOLVWLQJVDQGEHWUHDWHGDV
PLVVLQJ LQ VXPPDU\ WDEOHV DQG SORWV )RU WKH SXUSRVH RI FDOFXODWLQJ 3. SDUDPHWHUV SUHGRVH
FRQFHQWUDWLRQV WKDW DUH OHVV WKDQ //24 DQG FRQFHQWUDWLRQV SULRU WR WKH ILUVW TXDQWLILDEOH
FRQFHQWUDWLRQWKDWDUHOHVVWKDQ//24ZLOOEHVHWWR]HURDQGDOORWKHUFRQFHQWUDWLRQVOHVVWKDQ
//24ZLOOEHVHWWRPLVVLQJ
$OODYDLODEOHSODVPDFRQFHQWUDWLRQWLPHGDWDDQGGHULYHG3.SDUDPHWHUYDOXHVZLOOEHLQFOXGHG
LQWKH3.GDWDVHWDQGOLVWHGDFFRUGLQJO\
7UHDWPHQWRI2XWOLHUV
,IWKHSUHGRVHFRQFHQWUDWLRQIRUDSURILOHLVJUHDWHUWKDQRI&PD[WKHQWKH3.SDUDPHWHUVIRU
WKDWSURILOHZLOOEHH[FOXGHGIURPVXPPDULHVDQGVWDWLVWLFDODQDO\VLV2WKHULQGLYLGXDOSODVPD
FRQFHQWUDWLRQV LI GHHPHG WR EH DQRPDORXV PD\ EH H[FOXGHG IURP WKH DQDO\VLV IROORZLQJ


6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ


DUHYLHZRIDYDLODEOHGRFXPHQWDWLRQHJELRDQDO\WLFDOUHSRUWFOLQLFDOGDWD$Q\VXFKH[FOXVLRQ
ZLOOEHFOHDUO\OLVWHGLQWKHVWXG\UHSRUWDORQJZLWKMXVWLILFDWLRQIRUH[FOXVLRQ
(QWLUHSODVPDFRQFHQWUDWLRQWLPHSURILOHVIRUDSDUWLFLSDQWPD\EHH[FOXGHGIROORZLQJUHYLHZRI
DYDLODEOH GRFXPHQWDWLRQ HJ ELRDQDO\WLFDO UHSRUW FOLQLFDO GDWD +RZHYHU UHVXOWV RI DQDO\VLV
ZLWKDQGZLWKRXWWKHH[FOXGHGSURILOHVPD\EHSUHVHQWHGLQWKHVWXG\UHSRUW$Q\VXFKH[FOXVLRQ
ZLOOEHFOHDUO\OLVWHGLQWKHVWXG\UHSRUWDORQJZLWKMXVWLILFDWLRQIRUH[FOXVLRQ
3KDUPDFRNLQHWLF([FOXVLRQV
3KDUPDFRNLQHWLF $QDO\VLV 5HSRUWLQJ DQG ([FOXVLRQ FULWHULD VKRXOG IROORZ WKH %06 3.
+DUPRQL]DWLRQGRFXPHQW9HUVLRQ6SHFLILFJXLGHOLQHIRUH[FOXVLRQDU\FULWHULDIRUKDOIOLIH
DQGKRZRWKHU3.SDUDPHWHUVDUHDIIHFWHGIRUH[FOXVLRQLVXQGHUVHFWLRQ RIWKH%063.
+DUPRQL]DWLRQGRFXPHQW
([FOXVLRQRIRQHRUPRUHSDUDPHWHUVRUWKHHQWLUHGDWDVHWPD\EHFRQVLGHUHGGXHWRLQFRPSOHWH
SURILOHVXFKDV$8&,1)RUZKHQ7+$/)FDQQRWEHUHOLDEO\FDOFXODWHGRUWKHUHLVQRVDPSOH
DURXQGWKHVXVSHFWHG&PD[,QDGGLWLRQSDUWLFLSDQWVPD\EHH[FOXGHGIURPWKHDQDO\VLVLIWKH\
PLVVHGGRVHVKDGGLDUUKHDRUYRPLWHGDWRUEHIRUHDWLPHHTXDOWRWZLFHWKHPHGLDQ7PD[IRU
LPPHGLDWHUHOHDVHSURGXFWVRUYRPLWHGDWDQ\WLPHGXULQJVDPSOLQJDIWHUWKHDGPLQLVWUDWLRQRI
PRGLILHGUHOHDVHIRUPXODWLRQV

&217(172)5(32576
6WDWLVWLFDO FRPSRQHQWV IRU WKH &65 ZLOO EH EDVHG RQ WKH FRQWHQW RI WKLV 6$3 'HWDLOV RI WKH
WDEOHVOLVWLQJVDQGILJXUHVWREHSUHSDUHGIRUWKHILQDO&65ZLOOEHLQFOXGHGLQDVWXG\VSHFLILF
'DWD3UHVHQWDWLRQ3ODQ'33




6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ



/LVWRI$EEUHYLDWLRQV
7DEOH
/LVWRI$EEUHYLDWLRQV
$(
DGYHUVHHYHQW
$8&
DUHDXQGHUWKHFRQFHQWUDWLRQWLPHFXUYH
$8&7
DUHDXQGHUWKHSODVPDFRQFHQWUDWLRQWLPHFXUYHIURPWLPH]HURWRWLPHRIODVWTXDQWLILDEOH
FRQFHQWUDWLRQ
$8&,1)
DUHDXQGHUWKHSODVPDFRQFHQWUDWLRQWLPHFXUYHIURPWLPH]HURH[WUDSRODWHGWRLQILQLWHWLPH
%06
%ULVWRO0\HUV6TXLEE
%3
EORRGSUHVVXUH
&,
FRQILGHQFHLQWHUYDO
&PD[
PD[LPXPREVHUYHGFRQFHQWUDWLRQ
&65
FOLQLFDOVWXG\UHSRUW
&9
FRHIILFLHQWRIYDULDWLRQ
);D
)DFWRU;D
(&*
HOHFWURFDUGLRJUDP
)UHO
UHODWLYHELRDYDLODELOLW\
*05
JHRPHWULFPHDQUDWLR
,&)
LQIRUPHGFRQVHQWIRUP
//24
ORZHUOLPLWRITXDQWLILFDWLRQ
1
QXPEHURISDUWLFLSDQWV
37
SUHIHUUHGWHUP
3.
SKDUPDFRNLQHWLFV
47F)
47LQWHUYDOFRUUHFWHGIRUKHDUWUDWHXVLQJ)ULGHULFLD¶VIRUPXOD
6$(
VHULRXVDGYHUVHHYHQW
6$3
VWDWLVWLFDODQDO\VLVSODQ
6'
VWDQGDUGGHYLDWLRQ
6(
VWDQGDUGHUURU
62&
V\VWHPRUJDQFODVV
7+$/)
WHUPLQDOKDOIOLIH
7PD[
WLPHRIPD[LPXPREVHUYHGSODVPDFRQFHQWUDWLRQ
81
XQVWUXFWXUHG



6WDWLVWLFDO$QDO\VLV3ODQ
&9
%06
$SL[DEDQ




























































